<SEC-DOCUMENT>0001628280-22-004300.txt : 20220228
<SEC-HEADER>0001628280-22-004300.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228172705
ACCESSION NUMBER:		0001628280-22-004300
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220228
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		22691681

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8548

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20220228.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:aec18fb2-6110-4082-a409-d742dcaf2e3d,g:0ce9a24c-0bad-4576-a9f4-8c303ed05681,d:fda0a7f4e4fa4c2c833e9ab10b95ab52--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20220228</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml80L2ZyYWc6YTg2M2I4YWY2NGQ2NGE5Yjg0ZmQ5ZWU5NDU3ZmE5Y2MvdGFibGU6NGRiM2I3MTAxMmJjNDY1M2E4YTYzNTA0OGI0MWM2NWUvdGFibGVyYW5nZTo0ZGIzYjcxMDEyYmM0NjUzYThhNjM1MDQ4YjQxYzY1ZV8yLTEtMS0xLTc0MTc1_ec676274-a915-414e-bb59-8da274b73e92">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml80L2ZyYWc6YTg2M2I4YWY2NGQ2NGE5Yjg0ZmQ5ZWU5NDU3ZmE5Y2MvdGFibGU6NGRiM2I3MTAxMmJjNDY1M2E4YTYzNTA0OGI0MWM2NWUvdGFibGVyYW5nZTo0ZGIzYjcxMDEyYmM0NjUzYThhNjM1MDQ4YjQxYzY1ZV8zLTEtMS0xLTc0MTc1_0f6544d7-45f9-4210-bebe-eed828ed2930">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20220228.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifda0a7f4e4fa4c2c833e9ab10b95ab52_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDEz_9ed5222b-1660-4e02-9727-4b5c5171b831">8-K</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8yMjg_9aa5eb52-0022-4e14-bbad-e7560ae5b3cd">February 28, 2022</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDEx_06da7f57-45e7-42e7-99e8-1ee90c0a330f">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.774%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MWE0NzRlZGM4Zjg5NDc3ZWJlYjA5NGZlMDQ2OTU1NDcvdGFibGVyYW5nZToxYTQ3NGVkYzhmODk0NzdlYmViMDk0ZmUwNDY5NTU0N18wLTAtMS0xLTc0MTc1_dabcf8d6-2e7c-4935-a402-0aa5c2126e98">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MWE0NzRlZGM4Zjg5NDc3ZWJlYjA5NGZlMDQ2OTU1NDcvdGFibGVyYW5nZToxYTQ3NGVkYzhmODk0NzdlYmViMDk0ZmUwNDY5NTU0N18wLTItMS0xLTc0MTc1_8041de92-c194-48dd-acef-1a4aab848a90">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MWE0NzRlZGM4Zjg5NDc3ZWJlYjA5NGZlMDQ2OTU1NDcvdGFibGVyYW5nZToxYTQ3NGVkYzhmODk0NzdlYmViMDk0ZmUwNDY5NTU0N18wLTQtMS0xLTc0MTc1_fba7ba96-0693-4bf6-8f89-40a195a818b9">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA5_437a1b8d-e3b1-4803-87fe-4ef2ab7c40c4">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA2_8e2c5afc-8352-416b-a627-6d9025ceb12d">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA3_e89b9a5c-c8b1-4959-a19f-13bfe8a5e955">California</ix:nonNumeric> <ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8zNzA_2ca46a74-2203-4af1-a94d-9d634010fe7c">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA4_dd15390d-18b3-4da5-9ef4-7595762f05bb">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDEy_0a7469e2-6fe0-49e9-a9b8-35ce9d456f05">866-8548</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.858%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8wLTAtMS0xLTc0MTc1_b0d740e4-b95c-470b-9fac-ec1511f147c0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8xLTAtMS0xLTc0MTc1_13dcb63a-9602-48fb-8857-def4cd98fb91">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8yLTAtMS0xLTc0MTc1_e53bb13f-9004-4291-8e89-8266066e078f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8zLTAtMS0xLTc0MTc1_760b8d7d-0e80-4575-9c41-3c7b3aa00049">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6NThiMmJlMWRhOTJmNDI1Mjg3NGQyNGI2MzAxNTg4YWYvdGFibGVyYW5nZTo1OGIyYmUxZGE5MmY0MjUyODc0ZDI0YjYzMDE1ODhhZl8wLTEtMS0xLTc0MTc1_9e047859-0b08-4595-9f99-a2044e79d742">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:39.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6YzBkOTliMTM1MWZmNDU1NTlhOTE4M2I5NmM5NzAyNDYvdGFibGVyYW5nZTpjMGQ5OWIxMzUxZmY0NTU1OWE5MTgzYjk2Yzk3MDI0Nl8xLTAtMS0xLTc0MTc1_d3219a19-0a24-47b3-95ff-cb07a5a697ef">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6YzBkOTliMTM1MWZmNDU1NTlhOTE4M2I5NmM5NzAyNDYvdGFibGVyYW5nZTpjMGQ5OWIxMzUxZmY0NTU1OWE5MTgzYjk2Yzk3MDI0Nl8xLTEtMS0xLTc0MTc1_1dc7e17e-1767-42c5-b649-fc49c1237c6a">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6YzBkOTliMTM1MWZmNDU1NTlhOTE4M2I5NmM5NzAyNDYvdGFibGVyYW5nZTpjMGQ5OWIxMzUxZmY0NTU1OWE5MTgzYjk2Yzk3MDI0Nl8xLTItMS0xLTc0MTc1_b0e0f7ee-9a8f-4296-8134-ca4972832cf0">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifda0a7f4e4fa4c2c833e9ab10b95ab52_86"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Item 1.01&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement.</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;28, 2022, Denali Therapeutics Inc. (the &#8220;Company&#8221;) entered into an equity distribution agreement (the &#8220;Agreement&#8221;) with Goldman Sachs &amp; Co. LLC (&#8220;Goldman&#8221;), SVB Securities LLC (&#8220;SVB Securities&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), pursuant to which the Company may offer and sell shares of the Company&#8217;s common stock, par value $0.01 per share, having aggregate gross proceeds of up to $400 million from time to time, through an &#8220;at the market offering&#8221; program under which Goldman, SVB Securities and Cantor will act as sales agents. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the sales agents. </span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, the Company will set the parameters for the sale of shares, including the number or dollar value of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Agreement, the sales agents may sell the shares by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The sales agents will use their commercially reasonable efforts in conducting such sales activities consistent with their normal trading and sales practices, on mutually agreed terms between the sales agents and the Company. The Company is not obligated to sell, and the sales agents are not obligated to sell, any shares of common stock under the Agreement. No assurance can be given that the Company will sell any shares of common stock under the Agreement, or, if it does, as to the price or amount of shares of common stock that it sells or the dates when such sales will take place. The Agreement may be terminated by the Company or any of the sales agents by written notice to the other parties at any time, subject to the terms and conditions of termination as described in the Agreement.</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement provides that the sales agents will be entitled to compensation for their services equal to up to 3.0% of the gross proceeds of any shares sold through the sales agents under the Agreement. The sales agents and the Company have no obligation to sell any shares under the Agreement and may at any time, upon notice to the other parties, suspend solicitation and offers under the Agreement. </span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Agreement, the Company has agreed to indemnify the sales agents against certain liabilities, including under the Securities Act and to contribute payments that the sales agents may be required to make because of such liabilities. Further, the sales agents have agreed to indemnify the Company, the Company&#8217;s board of directors and its executive officers against certain liabilities, including under the Securities Act.</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock sold pursuant to the Agreement will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3, including the prospectus supplement contained therein, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;28, 2022, which was automatically effective upon filing with the SEC.</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifda0a7f4e4fa4c2c833e9ab10b95ab52_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:9pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:1.28pt"> Exhibits</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit11-8xk.htm">Equity Distribution Agreement between the Company and Goldman Sachs &amp; Co. LLC, SVB Securities LLC and Cantor Fitzgerald &amp; Co., dated as of February 28, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifda0a7f4e4fa4c2c833e9ab10b95ab52_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit11-8xk.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia20891ed49c841ec8918b3ac741a3b94_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 1.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DENALI THERAPEUTICS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock ($0.01 par value) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Having an Aggregate Offering Price of up to $400,000,000</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Equity Distribution Agreement</font></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">February 28, 2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Goldman, Sachs &#38; Co. LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">200 West Street</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10282</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SVB Securities LLC </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">255 California Street</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">San Francisco, CA 94111</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cantor Fitzgerald &#38; Co.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">499 Park Avenue</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10022</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Denali Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) confirms its agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with Goldman, Sachs &#38; Co. LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goldman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), SVB Securities LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SVB Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Cantor Fitzgerald &#38; Co. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Description of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company proposes to issue and sell through or to the Managers, as sales agents and&#47;or principals, shares of the Company&#8217;s common stock, $0.01 par value (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) having an aggregate offering price of up to $400,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), from time to time during the term of this Agreement and on the terms set forth in Section&#160;3 of this Agreement. The Company hereby appoints the Managers as exclusive agents of the Company for the purpose of making offers and sales of the Shares. The Company agrees that whenever it determines to sell the Shares directly to a Manager as principal, it will enter into a separate agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Terms Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in substantially the form of Annex I hereto, relating to such sale in accordance with Section&#160;3 of this Agreement. Certain terms used herein are defined in Section 19 hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company represents and warrants to, and agrees with, the Managers at the Execution Time and on each such time the following representations and warranties are repeated or deemed to be made pursuant to this Agreement, as set forth below.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. &#160;The Company meets the requirements for use of Form S-3 under the Act and has prepared and filed, or will file, with the Commission an automatic shelf registration statement on Form S-3, including a related Base Prospectus, for registration under the Act of the offering and sale of the Shares and other securities of the Company. Such Registration Statement, including any amendments thereto filed prior to the Execution Time or prior to any such time this representation is repeated or deemed to be made, became effective upon filing and no stop order suspending the effectiveness of the Registration Statement has been </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                                                                                                                                                                       </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">issued under the Act and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission, and any request on the part of the Commission for additional or supplemental information has been complied with. The Company shall file with the Commission the Prospectus Supplement relating to the Shares in accordance with Rule 424(b) promptly after the Execution Time (but in any event in the time period prescribed thereby). As filed, the Prospectus complied in all material respects with the requirements of the Act and the rules thereunder, and, except to the extent the Managers shall agree in writing to a modification, shall be in all substantive respects in the form furnished to the Managers prior to the Execution Time or prior to any such time this representation is repeated or deemed to be made. The Registration Statement, at the Execution Time, each such time this representation is repeated or deemed to be made, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 or any similar rule) in connection with any offer or sale of Shares, meets the requirements set forth in Rule 415(a)(1)(x). The initial Effective Date of the Registration Statement was not earlier than the date three years before the Execution Time. Any reference herein to the Registration Statement, the Base Prospectus, the Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, the Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus, as the case may be&#59; and any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the Base Prospectus, the Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, the Prospectus Supplement, any Interim Prospectus Supplement or the Prospectus, as the case may be, deemed to be incorporated therein by reference. Notwithstanding the foregoing, the representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement or any post-effective amendment or the Prospectus or any amendments or supplements thereto, made in reliance upon and in conformity with information furnished to the Company in writing by the Managers relating to the Managers expressly for use therein.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successor Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent that the Registration Statement is not available for the sales of the Shares as contemplated by this Agreement, the Company shall file a new registration statement with respect to any additional Common Stock necessary to complete such sales of the Shares and shall cause such registration statement to become effective as promptly as practicable. After the effectiveness of any such registration statement, all references to &#8220;Registration Statement&#8221; included in this Agreement shall be deemed to include such new registration statement, including all documents incorporated by reference therein pursuant to Item 12 of Form S-3, and all references to &#8220;Base Prospectus&#8221; included in this Agreement shall be deemed to include the final form of prospectus, including all documents incorporated therein by reference, included in any such registration statement at the time such registration statement became effective.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Material Misstatements or Omissions in the Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On each Effective Date, at the Execution Time, at each deemed effective date with respect to the Managers pursuant to Rule 430B(f)(2) under the Act, at each Applicable Time, at each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement Date, at each Time of Delivery and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 or any similar rule) in connection with any offer or sale of Shares, the Registration Statement complied and will comply in all material respects with the applicable requirements of the Act and the rules thereunder and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading&#59; and on the date of any filing pursuant to Rule 424(b), at each Applicable Time, on each Settlement Date, at each Time of Delivery and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 or any similar rule) in connection with any offer or sale of Shares, the Prospectus (together with any supplement thereto) complied and will comply in all material respects with the applicable requirements of the Act and the rules thereunder and did not and will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Prospectus (or any supplement thereto) in reliance upon and in conformity with information furnished in writing to the Company by the Managers specifically for inclusion in the Registration Statement or the Prospectus (or any supplement thereto).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At the Execution Time, at each Applicable Time, at each Settlement Date and each Time of Delivery, the Disclosure Package does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from the Disclosure Package based upon and in conformity with written information furnished to the Company by the Managers specifically for use therein.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporated Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus (i) at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission thereunder and (ii) when read together with the other information in the Prospectus and the Disclosure Package at any Applicable Time and when read together with the other information in the Prospectus at the date of the Prospectus and at any Settlement Date or Time of Delivery, will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Other Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by means of any &#8220;prospectus&#8221; (within the meaning of the Act) or used any &#8220;prospectus&#8221; (within the meaning of the Act) in connection with the offer or sale of the Shares, and from and after the execution of this Agreement, the Company will not, directly or indirectly, offer or sell any Shares by means of any &#8220;prospectus&#8221; (within the meaning of the Act) or use any &#8220;prospectus&#8221; (within the meaning of the Act) in connection with the offer or sale of the Shares, other than the Prospectus, as amended </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or supplemented from time to time in accordance with the provisions of this Agreement&#59; the Company has not, directly or indirectly, prepared, used or referred to any Issuer Free Writing Prospectus in connection with the offering of the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Stop Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Registration Statement is not the subject of a pending proceeding or examination under Section&#160;8(d) or 8(e) of the Act, and the Company is not the subject of a pending proceeding under Section&#160;8A of the Act in connection with the offering of the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Common Stock constitutes an &#8220;actively-traded security&#8221; exempted from the requirements of Rule 101 of Regulation M under the Exchange Act by subsection (c)(1) of such rule.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sales Agency Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has not entered into any other sales agency agreements or other similar arrangements with any agent or any other representative in respect of any at the market offering (within the meaning of Rule 415(a)(4) under the Act) of the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Offering Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. &#160;&#160;&#160;&#160;The Company has not distributed and will not distribute, prior to the termination of this Agreement, any offering material in connection with the offering and sale of the Shares other than the Prospectus and any Issuer Free Writing Prospectus reviewed and consented to by the Managers and identified in Schedule I hereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Material Adverse Change in Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included or incorporated by reference in the Disclosure Package, (i) sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree or (ii) entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole, in each case otherwise than as set forth or contemplated in the Disclosure Package and the Prospectus&#59; and, since the respective dates as of which information is given in the Registration Statement, the Disclosure Package and the Prospectus, there has not been (x) any change in the capital stock (other than as a result of (i) the exercise, if any, of stock options or the award, if any, of stock options or restricted stock in the ordinary course of business pursuant to the Company&#8217;s equity plans that are described in the Prospectus or (ii) the issuance, if any, of stock upon conversion of Company securities as described in the Prospectus) or long term debt of the Company or any of its subsidiaries or (y) any Material Adverse Effect (as defined below)&#59; as used in this Agreement, &#8220;Material Adverse Effect&#8221; shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i) the business, properties, general affairs, management, financial position, stockholders' equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Registration Statement, the Disclosure Package and the Prospectus, or (ii) the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Prospectus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Statistical and Market-Related Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;    Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in the Registration Statement, the Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Title to Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company and its subsidiaries have good and marketable title to all personal property (other than with respect to Intellectual Property (as defined below), which is addressed exclusively in subsection (i) below) owned by them, in each case free and clear of all liens, encumbrances and defects except such as are described in the Registration Statement, the Disclosure Package and the Prospectus or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries&#59; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under, to the Company&#8217;s knowledge, valid, subsisting and enforceable leases (subject to the effects of (i) bankruptcy, insolvency, fraudulent conveyance, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights or remedies of creditors generally&#59; (ii) the application of general principles of equity&#59; and (iii) applicable law and public policy with respect to rights to indemnity and contribution)  with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;   The Company and its subsidiaries own or possess sufficient rights to use all owned or in-licensed patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works, know-how, trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (including all goodwill associated with the foregoing) (collectively, &#8220;Intellectual Property&#8221;) material to the conduct of their businesses as presently conducted or currently proposed to be conducted in the Registration Statement, the Disclosure Package and the Prospectus.  Except as described in the Registration Statement, the Disclosure Package and the Prospectus, to the knowledge of the Company, the Company and its subsidiaries have not materially infringed, misappropriated or otherwise violated any Intellectual Property of any person and the conduct of its business as presently conducted or as proposed to be conducted in the Registration Statement, the Disclosure Package and the Prospectus does not and will not infringe, misappropriate or otherwise violate any Intellectual Property of any person. Except as would not reasonably be expected to have a Material Adverse Effect, or except as described in the Registration Statement, the Disclosure Package and the Prospectus, there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim (i) challenging the Company&#8217;s or any of its subsidiaries&#8217; rights in or to, or alleging the violation of any of the terms of, any of their Intellectual Property&#59; (ii) alleging that the Company or any of its subsidiaries have infringed, misappropriated or otherwise violated or conflicted with any Intellectual Property of any third party&#59; or (iii) challenging the validity, scope or enforceability of any Intellectual Property owned by or exclusively licensed to the Company or any of its subsidiaries.  Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, or except as described in the Registration Statement, the Disclosure Package and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prospectus, (w) all Intellectual Property owned by or licensed to the Company or any of its subsidiaries (1) is, to the knowledge of the Company, valid and enforceable, (2) is solely owned by or, licensed or co-licensed by the Company or one or more of its subsidiaries, and (3)&#160;is owned free and clear of all liens, encumbrances, defects and other restrictions, and (x) to the knowledge of the Company, no third party has infringed, misappropriated or otherwise violated any Intellectual Property owned by or exclusively licensed to the Company or any of its subsidiaries.  The Company and its subsidiaries have at all times taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of all material Intellectual Property the value of which to the Company and its subsidiaries is contingent upon maintaining the confidentiality thereof.  All founders, current and former employees, contractors, consultants and other parties involved in the development of material Intellectual Property for the Company and its subsidiaries have signed confidentiality and invention assignment agreements with the Company or its subsidiaries, pursuant to which the Company and its subsidiaries either (y) have obtained ownership of and are the exclusive owner of such material Intellectual Property, or (z) have obtained a valid right to exploit such material Intellectual Property, sufficient for the conduct of their businesses as currently conducted and as proposed in the Registration Statement, the Disclosure Package and the Prospectus to be conducted.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">IT Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Except as would not reasonably be expected to result in a Material Adverse Effect on the Company and its subsidiaries taken as a whole, the Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of the Company and its subsidiaries) (collectively, &#8220;IT Systems&#8221;)  operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries, and, to the knowledge of the Company, are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have used reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with, reasonable information technology, information security, cyber security and data protection controls, policies, procedures and safeguards, including oversight, access controls, encryption, technological and physical safeguards and business continuity&#47;disaster recovery and security plans that are necessary to protect against and prevent breach, destruction, loss, unauthorized distribution, use, disruption, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any information technology system or personal, personally identifiable, household, sensitive, confidential or regulated data (&#8220;Data&#8221;) in its possession or control used in connection with the operation of the Company&#8217;s and its subsidiaries&#8217; businesses (&#8220;Breach&#8221;). To the knowledge of the Company, there has been no such Breach except as would not reasonably be expected to have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole. The Company and its subsidiaries have not been notified of and have no knowledge of any event or condition that would reasonably be expected to result in, any such Breach.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cybersecurity&#59; Data Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.     (i) The Company and its subsidiaries have complied, and are presently in compliance, in all material respects, with all internal and external privacy policies, contractual obligations, industry standards, applicable laws, statutes, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">judgments, orders, rules and regulations of any court or arbitrator or other governmental or regulatory authority and any legal obligations regarding the collection, use, transfer, import, export, storage, protection, disposal and disclosure by the Company and its subsidiaries of Data (&#8220;Data Security Obligations&#8221;)&#59; (ii) neither the Company nor any of its subsidiaries has received any notification of or complaint regarding, and are aware of any other facts that, individually or in the aggregate, would reasonably indicate non-compliance with any Data Security Obligation&#59; and (iii) there is no pending, or to the knowledge of the Company, threatened, action, suit or proceeding by or before any court or governmental agency, authority or body pending or threatened alleging non-compliance with any Data Security Obligation.  The Company and its subsidiaries have taken steps reasonably necessary in accordance with industry standard practices to protect such information against loss and against unauthorized access, use, modification, disclosure or other misuse, except in each case to the extent that the failure to do so would not reasonably be expected to have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole. To the knowledge of the Company, except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus or as would not individually or in the aggregate have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole, there has been no unauthorized access to such information. The Company and its subsidiaries have taken or will take all necessary actions to comply with all applicable laws and regulations with respect to Personal Data that have been announced as of the date hereof as becoming effective within 12 months after the date hereof, and for which any non-compliance with same would be reasonably likely to have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole, as soon they take effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Licenses and Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    The Company possesses all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are required for the ownership or lease of its property or the conduct of its businesses as currently conducted and described in the Registration Statement, the Disclosure Package and the Prospectus, including, without limitation, from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect&#59; and except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not received notice of any revocation of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in the ordinary course.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matters.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The Company has operated and currently is in compliance with all applicable rules and regulations of the FDA, except where the failure to so operate or be in compliance would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Data and Regulatory Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   Any studies, tests and preclinical and clinical trials conducted by the Company and, to the knowledge of the Company, any studies, tests and preclinical and clinical trials conducted on behalf of the Company or in which the Company has participated, were, and if still pending are, being conducted in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable rules and regulations, including those of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FDA and comparable regulatory agencies outside of the United States, to which the Company is subject and, for studies submitted to regulatory authorities as a basis for regulatory approval and preclinical and clinical trials, current Good Clinical Practices and Good Laboratory Practices, except where the failure to be so conducted would not reasonably be expected to have a Material Adverse Effect&#59; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Disclosure Package and the Prospectus are, to the Company&#8217;s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials&#59; except to the extent disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development&#59; and, except to the extent disclosed in the Registration Statement, the Disclosure Package or the Prospectus, the Company has not received any notices or correspondence from the FDA or any other comparable federal, state, local or foreign governmental or regulatory authority requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Labor Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   No material labor disturbance by or dispute with employees of the Company exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers or contractors, except as would not have a Material Adverse Effect.  The Company has not received any notice of cancellation or termination with respect to any collective bargaining agreement material to the Company. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)) would have any liability (each, a &#8220;Plan&#8221;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, except for noncompliance that would not reasonably be expected to result in material liability to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption&#59; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan&#59; (iv) no Plan is, or is reasonably expected to be, in &#8220;at risk status&#8221; (within the meaning of Section 303(i) of ERISA) and no Plan that is a &#8220;multiemployer plan&#8221; within the meaning of Section 4001(a)(3) of ERISA is in &#8220;endangered status&#8221; or &#8220;critical status&#8221; (within the meaning of Sections 304 and 305 of ERISA) (v) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ERISA, the fair market value of the assets of each such Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan)&#59; (vi) no &#8220;reportable event&#8221; (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur&#59; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification&#59; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221; within the meaning of Section 4001(a)(3) of ERISA)&#59; and (ix) none of the following events has occurred or is reasonably likely to occur&#58; (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#8217;s and its Controlled Group affiliates&#8217; most recently completed fiscal year&#59; or (B) a material increase in the Company&#8217;s &#8220;accumulated post-retirement benefit obligations&#8221; (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in the Company&#8217;s most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    (i) Except in each case as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company (x) has complied and is in compliance with all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees and orders relating to pollution,  hazardous or toxic substances, wastes, pollutants, contaminants or the protection of human health or safety, the environment or natural resources (collectively, &#8220;Environmental Laws&#8221;)&#59; (y) has received and is in compliance with all permits, licenses, certificates or other authorizations or approvals required of it under any Environmental Laws to conduct its business&#59; and (z) has not received notice of any actual or potential liability of the Company, or obligation of the Company under or relating to, or any actual or potential violation of, any Environmental Laws by the Company, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect&#59; and (iii) except as described in each of the Registration Statement, the Disclosure Package and the Prospectus, (x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y) the Company is not aware of any facts regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">contaminants, that individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect, and (z) the Company does not anticipate material capital expenditures relating to any Environmental Laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Standing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    Each of the Company and its subsidiaries has been (i) duly organized and is validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own its properties and conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus, and (ii) duly qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, have a Material Adverse Effect&#59; and each subsidiary of the Company has been listed in the Registration Statement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    The Company has an authorized capitalization as set forth in the Registration Statement, the Disclosure Package and the Prospectus and all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and conform in all material respects to the description of the Stock contained in the Registration Statement, the Disclosure Package and the Prospectus&#59; and all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and (except, in the case of any foreign subsidiary, for directors&#8217; qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims, except for such liens or encumbrances described in the Registration Statement, the Disclosure Package and the Prospectus. The unissued Shares to be issued and sold by the Company to the Underwriters hereunder have been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and non-assessable and will conform in all material respects to the description of Stock contained in the Registration Statement, the Disclosure Package and the Prospectus&#59; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(y)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Conflict or Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;  The issue and sale of the Shares and the compliance by the Company with this Agreement and the consummation by the Company of the transactions contemplated in this Agreement and the Registration Statement, the Disclosure Package and the Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A) any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, except, in the case of this clause (A) for such defaults, breaches, or violations that would not, individually or in the aggregate, have a Material Adverse Effect, (B) the certificate of incorporation or by-laws (or other applicable organizational document) of the Company or any of its subsidiaries, or (C) any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of this clause (C) for such violations that would not, individually or in the aggregate, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">have a Material Adverse Effect&#59; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the issue and sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act, the approval by the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) of the underwriting terms and arrangements, the approval for listing on the NASDAQ Global Select Market (the &#8220;Exchange&#8221;) and such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the Managers.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(z)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Violations, Defaults and Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Neither the Company nor any of its subsidiaries is (i) in violation of its certificate of incorporation or by-laws (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, or (iii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii) and (iii), for such violations or defaults as would not, individually or in the aggregate, have a Material Adverse Effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Summaries of Law and Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The statements set forth in the Registration Statement, the Disclosure Package  and the Prospectus under the caption &#8220;Description of Capital Stock&#8221;, insofar as they purport to constitute a summary of the terms of the Stock, under the caption &#8220;Material U.S. Federal Income Tax Considerations for Non-U.S. Holders of our Common Stock&#8221;, and under the caption &#8220;Plan of Distribution&#8221;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all material respects.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(bb)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Other than as set forth in the Registration Statement, the Disclosure Package and the Prospectus, there are no legal or governmental proceedings pending to which the Company or any of its subsidiaries is a party or of which any property of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries (or such officer or director), would individually or in the aggregate have a Material Adverse Effect&#59; and, to the Company's knowledge, no such proceedings are threatened or contemplated by governmental authorities or threatened by others.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(cc)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Related Party Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   No relationship, direct or indirect, exists between the Company, on the one hand, and the directors, officers, or stockholders of the Company, on the other, that is required by the Act to be described in the Registration Statement, the Disclosure Package and the Prospectus and that is not so described in such documents.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(dd)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Company Act.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof, will not be an &#8220;investment company&#8221;, as such term is defined in the Investment Company Act of 1940, as amended.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ee)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ineligible Issuer Status.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   (A) (i) At the time of filing the Registration Statement, (ii) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus), and (iii) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Act) made any offer relating to the Shares in reliance on the exemption of Rule 163 under the Act, the Company was a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405 under the Act&#59; and (B) at the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and is not an &#34;ineligible issuer,&#34; as defined under Rule 405 under the Act.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ff)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Rated Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    There are no debt securities or preferred stock issued or guaranteed by the Company that are rated by a &#8220;nationally recognized statistical rating organization&#8221;, as such term is defined under Section 3(a)(62) under the Exchange Act.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(gg)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Act, other than shares issued pursuant to employee benefit plans or other employee compensation plans or pursuant to outstanding options, rights or warrants.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(hh)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.     Ernst &#38; Young LLP who have certified certain financial statements of the Company and its subsidiaries are independent public accountants as required by the Act and the rules and regulations of the Commission thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act that (i) complies with the requirements of the Exchange Act applicable to the Company and, (ii) has been designed by the Company's principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and (iii) is sufficient to provide reasonable assurance that (A) transactions are executed in accordance with management&#8217;s general or specific authorization, (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets, (C) access to assets is permitted only in accordance with management&#8217;s general or specific authorization and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences&#59; and the Company is not aware of any material weaknesses in its internal control over financial reporting (it being understood that this subsection shall not require the Company to comply with Section 404 of the Sarbanes-Oxley Act of 2002 as of an earlier date than it would otherwise be required to so comply under applicable law).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(jj)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Accounting Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.     Since the date of the latest audited financial statements included or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, there has been no change in the Company&#8217;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(kk)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act applicable to the Company&#59; such disclosure controls and procedures have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company&#8217;s principal executive officer and principal financial officer by others within those entities&#59; and such disclosure controls and procedures are effective.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ll)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with the Sarbanes-Oxley Act,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   The Company was and is in compliance with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith that the Company was required to be in compliance with upon the effectiveness of the Registration Statement, including Section 402 related to loans.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(mm)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   Except as described in or expressly contemplated by the Registration Statement, the Disclosure Package and the Prospectus, the Company has insurance covering its property, operations, personnel and businesses, including clinical trial insurance and business interruption insurance, which insurance is, in the Company&#8217;s reasonable judgment, in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the Company believes are reasonably adequate to protect the Company and its business&#59; and the Company has not (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(nn)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Absence of Further Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    The Company has all requisite rights, power and authority to execute and delivery this Agreement and to perform its obligations hereunder&#59; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(oo)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement has been duly authorized, executed and delivered by the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(pp)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption and Anti-Bribery Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.     None of the Company nor any of its subsidiaries nor any of its or their directors, officers, employees, affiliates nor, to the knowledge of the Company, any agent or other person associated with or acting on behalf of the Company or any of its subsidiaries (i) has made, offered, promised or authorized or will make, offer, promise or authorize any unlawful contribution, gift, entertainment or other unlawful expense&#59; (ii) has made, offered, promised or authorized or will make, offer, promise or authorize </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any direct or indirect unlawful payment&#59; or (iii) has violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law&#59; the Company and its affiliates have conducted their businesses in compliance with applicable anti-bribery and anti-corruption laws and have instituted and maintain policies and procedures designed to promote and achieve compliance with such laws and with the representation and warranty contained herein&#59; and the Company will not use, directly or indirectly, the proceeds of the offering and sale of the Shares in furtherance of an offer, payment, promise to pay or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-bribery or anti-corruption laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(qq)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Finder&#8217;s Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    Except as described in the Registration Statement, the Disclosure Package or the Prospectus, Company is not a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any Managers for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(rr)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.      No person has the right to require the Company to register any securities for sale under the Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares, except such rights that have been waived or complied with.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ss)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stabilization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Company has not taken, directly or indirectly, without giving effect to activities by the Managers or affiliate or agent of any manager acting on behalf of such manager, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(tt)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;  The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the applicable anti-money laundering laws of the various jurisdictions in which the Company and its subsidiaries conduct business (collectively, the &#8220;Money Laundering Laws&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(uu)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;  None of the Company or any of its subsidiaries nor, to the knowledge of the Company, its or their directors or officers, or any agent, employee or affiliate of the Company or any of its subsidiaries is, or is owned or controlled by one or more individuals or entities that is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;OFAC&#8221;), or the U.S. Department of State and including, without limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person,&#8221; the European Union, Her Majesty&#8217;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;), nor is the Company or any of its subsidiaries </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria)&#59; the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person, or in any country or territory, that, at the time of such funding, is the subject or the target of Sanctions or (ii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions&#59; and for the past five years, the Company has not knowingly engaged in and is not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or target of Sanctions or with any Sanctioned country.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company has paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof (after giving effect to any valid extensions with respect to the filing of tax returns), except where the failure to pay or file would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, or except as described in the Registration Statement, the Disclosure Package and the Prospectus&#59; and except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, there are no tax deficiencies that have been, or would reasonably be expected to be, asserted against the Company or any of its property or assets and which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ww)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Statements&#59; Non-GAAP Financial Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The financial statements included in the Registration Statement, the Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of the Company and its subsidiaries at the dates indicated and the statement of operations, stockholders&#8217; equity and cash flows of the Company and its subsidiaries for the periods specified&#59; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;)  applied on a consistent basis throughout the periods involved.  The supporting schedules, if any, present fairly, in all material respects in accordance with GAAP the information required to be stated therein.  The selected financial data and the summary financial information included in the Registration Statement, the Disclosure Package and the Prospectus present fairly in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein.  Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, the Disclosure Package and the Prospectus under the Act or the rules and regulations promulgated thereunder.  All disclosures contained in the Registration Statement, the Disclosure Package and the Prospectus regarding &#8220;non-GAAP financial measures&#8221; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Act, to the extent applicable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to the Managers or to counsel for the Managers in connection with this Agreement or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any Terms Agreement shall be deemed a representation and warranty by the Company or such subsidiary of the Company, as applicable, to each Manager as to the matters set forth therein.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges that the Managers and, for purposes of the opinions to be delivered pursuant to Section&#160;4 hereof, counsel for the Company and counsel for the Managers, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale and Delivery of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Managers agree that the Company may from time to time seek to sell Shares through a Designated Manager, acting as sales agent, or directly to any of the Managers acting as principal, as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company may submit to a Designated Manager its orders (including any price, time or size limits or other customary parameters or conditions) to sell Shares on any Trading Day (as defined herein) in a form and manner as mutually agreed to by the Company and such Designated Manager. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any trading day on the NASDAQ.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the terms and conditions hereof, each Manager, at any time it is a Designated Manager, shall use its reasonable efforts to execute any Company order submitted to it hereunder to sell Shares and with respect to which such Designated Manager has agreed to act as sales agent. The Company acknowledges and agrees that (i)&#160;there can be no assurance that a Designated Manager will be successful in selling the Shares, (ii)&#160;a Designated Manager will incur no liability or obligation to the Company or any other person or entity if it does not sell Shares for any reason other than a failure by a Designated Manager to use its reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Shares as required under this Agreement and (iii)&#160;no Manager shall be under any obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by a Manager and the Company. The Designated Manager may make sales pursuant to each order by any method permitted by law, including without limitation (i) by means of ordinary brokers&#8217; transactions (whether or not solicited), (ii) to or through a market maker, (iii) directly on or through any national securities exchange or facility thereof, a trading facility of a national securities association, an alternative trading system, or any other market venue, (iv) in the over-the-counter market, (v) in privately negotiated transactions, or (vi) through a combination of any such methods. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Company shall not authorize the issuance and sale of, and a Designated Manager shall not sell as sales agent, any Share at a price lower than the minimum price therefor designated from time to time by the Company and notified to a Designated Manager in writing. In addition, the Company or a Designated Manager may upon notice to the other party hereto by telephone (confirmed promptly by email or facsimile), suspend an offering of the Shares with respect to which that Designated Manager is acting as sales agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such suspension or termination shall not affect or impair the parties&#8217; respective obligations with respect to the Shares sold hereunder prior to the giving of such notice.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The compensation to a Designated Manager for sales of the Shares with respect to which such Designated Manager acts as sales agent hereunder shall be up to 3.00% of the gross offering proceeds of the Shares sold pursuant to this Agreement as mutually agreed to in writing by such Designated Manager and the Company.  The foregoing rate of compensation shall not apply when a Manager, acting as principal, purchases Shares from the Company pursuant to a Terms Agreement. Any compensation or commission due and payable to any Managers hereunder with respect to any sale of Shares shall be paid by the Company to such Managers concurrently with the settlement for sales of the Shares by deduction from the proceeds from sales of the Shares payable to the Company. The remaining proceeds, after further deduction for any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales shall constitute the net proceeds to the Company for such Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Settlement for sales of the Shares pursuant to this Agreement will occur on the second Trading Day following the date on which such sales are made (each such day, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). On each Settlement Date, the Shares sold through a Designated Manager for settlement on such date shall be issued and delivered by the Company to such Designated Manager against payment of the Net Proceeds from the sale of such Shares. Settlement for all such Shares shall be effected by free delivery of the Shares, in definitive form, by the Company or its transfer agent to such Designated Manager&#8217;s or its designee&#8217;s account (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such Designated Manager shall have given the Company written notice of such designee at least one calendar day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto, in return for payments in same day funds delivered to the account designated by the Company. If the Company, or its transfer agent (if applicable) shall default on its obligation to deliver the Shares on any Settlement Date, the Company shall (i)&#160;hold each applicable Designated Manager harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and (ii)&#160;pay each such Designated Manager any commission, discount or other compensation to which it would otherwise be entitled absent such default.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;If acting as sales agent hereunder, the Designated Manager shall provide written confirmation (which may be by facsimile or email) to the Company following the close of trading on the NASDAQ each day in which the Shares are sold under this Agreement setting forth (i)&#160;the amount of the Shares sold on such day and the gross offering proceeds received from such sale and (ii)&#160;the commission payable by the Company to such Designated Manager with respect to such sales.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;At each Applicable Time, Settlement Date, Representation Date (as defined in Section&#160;4(k)) and Filing Date (as defined in Section&#160;4(r)), the Company shall be deemed to have affirmed each representation and warranty contained in this Agreement as if such representation and warranty were made as of such date, modified as necessary to relate to the Registration Statement and the Prospectus as amended as of such date. Any obligation of a Designated Manager to use its reasonable efforts to sell the Shares on behalf of the Company as sales agent shall be subject to the continuing accuracy of the representations and warranties of the Company herein (and the completion of any diligence to verify such accuracy by such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Designated Manager), to the performance by the Company of its obligations hereunder and to the continuing satisfaction of the additional conditions specified in Section 6 of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Subject to such further limitations on offers and sales of Shares or delivery of instructions to offer and sell Shares as are set forth herein and as may be mutually agreed upon by the Company and a Designated Manager, the Company shall not request the sale of any Shares that would be sold, and no Designated Manager shall be obligated to sell, (i)&#160;during any period in which the Company&#8217;s insider trading policy, as it exists on the date of this Agreement, would prohibit the purchase or sale of any Shares by any of its officers or directors, (ii) any time during the period commencing on the tenth business day prior to the time Company shall issue a press release containing, or shall otherwise publicly announce, its earnings, revenues or other results of operations (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Earnings Announcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) through and including the time that is 24 hours after the time that the Company files (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Filing Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) a Quarterly Report on Form 10-Q or an Annual Report on Form 10-K that includes consolidated financial statements as of and for the same period or periods, as the case may be, covered by such Earnings Announcement, or (iii)&#160;during any other period in which the Company is, or could be deemed to be, in possession of material non-public information.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;If the Company wishes to issue and sell the Shares pursuant to this Agreement directly to any of the Managers acting as principal (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), it will notify the Manager or Managers of the proposed terms of such Placement. If such Manager or Managers, acting as principal, wishes to accept such proposed terms (which a Manager may decline to do for any reason in its sole discretion) or, wishes to accept amended terms proposed by the Company after further discussion, such Manager or Managers and the Company will enter into a Terms Agreement setting forth the terms of such Placement. The terms set forth in a Terms Agreement will not be binding on the Company or such Manager or Managers unless and until the Company and such Manager or Managers have each executed such Terms Agreement accepting all of the terms of such Terms Agreement. In the event of a conflict between the terms of this Agreement and the terms of a Terms Agreement, the terms of such Terms Agreement will control.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Each Placement shall be made in accordance with the terms of this Agreement and, if applicable, a Terms Agreement, which will provide for the sale of such Shares to, and the purchase thereof by, such Manager. A Terms Agreement may also specify certain provisions relating to the reoffering of such Shares by a Manager. The commitment of a Manager to purchase the Shares pursuant to any Terms Agreement shall be deemed to have been made on the basis of the representations and warranties of the Company herein contained and shall be subject to the terms and conditions herein set forth. Each Terms Agreement shall specify the number of the Shares to be purchased by a Manager pursuant thereto, the price to be paid to the Company for such Shares, any provisions relating to rights of, and default by, underwriters acting together with such Manager in the reoffering of the Shares, and the time and date (each such time and date being referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Time of Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and place of delivery of and payment for such Shares. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Under no circumstances shall the number and aggregate amount of the Shares sold pursuant to this Agreement and any Terms Agreement exceed (i) the aggregate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">amount set forth in Section&#160;1, (ii) the number of shares of the Common Stock available for issuance under the currently effective Registration Statement or (iii) the number and aggregate amount of the Shares authorized from time to time to be issued and sold under this Agreement by the board of directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or a duly authorized committee thereof, and notified to the Managers in writing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees with each of the Managers that&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule 172 or any similar rule) to be delivered under the Act in connection with the offering or sale of the Shares, the Company will not file any amendment of the Registration Statement or supplement in connection with the offering and sale of the Shares (including the Prospectus Supplement or any Interim Prospectus Supplement) to the Base Prospectus, the Disclosure Package or the Prospectus, whether pursuant to the Act, the Exchange Act or otherwise, unless (i) the Company has furnished to the Managers a copy of such amendment or supplement (including, for the avoidance of doubt, reports or other information to be filed by the Company under the Exchange Act that would be incorporated by reference into the Registration Statement and the Prospectus) for its review a reasonable period of time prior to filing (or, in the case of Current Reports on Form 8-K, has used its commercially reasonable efforts to so furnish copies to the Managers prior to filing), and (ii) except for reports or other information required to be filed by the Company under the Exchange Act, the Company will not file any such proposed amendment or supplement to which the Managers reasonably object. The Company has prepared the Prospectus, in a form approved by the Managers, and shall file such Prospectus, as amended at the Execution Time, with the Commission pursuant to the applicable paragraph of Rule 424(b) promptly after the Execution Time (but in any event within the time period described thereby) and will cause any supplement to the Prospectus to be prepared, in a form approved by the Managers, and will file such supplement with the Commission pursuant to the applicable paragraph of Rule 424(b) within the time period prescribed thereby and will notify the Managers of such timely filing. The Company, subject to this Section&#160;4(a) and Section&#160;4(c), will comply with the requirements of Rule 430B. During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule 172 or any similar rule) to be delivered under the Act in connection with the offering or sale of the Shares, the Company will promptly advise the Managers (A) when the Prospectus, and any supplement thereto, shall have been filed (if required) with the Commission pursuant to Rule 424(b), (B) when, during any period when the delivery of a prospectus (whether physically or through compliance with Rule 172 or any similar rule) is required under the Act in connection with the offering or sale of the Shares, any amendment to the Registration Statement or any new registration statement relating to the Shares shall have been filed or become effective (other than a prospectus supplement relating solely to the offering of securities other than the Shares), (C) of the receipt of any comments from the Commission, (D) of any request by the Commission or its staff for any amendment of the Registration Statement, or for any supplement to the Prospectus or for any additional information related to the Registration Statement or the Prospectus, (E) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or of any notice objecting to its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">use or any the issuance of any order preventing or suspending the use of the Prospectus or any amendment or supplement thereto, or the institution or threatening of any proceeding for any of such purposes or pursuant to Section&#160;8A of the Act or (F) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its best efforts to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain at the earliest possible moment the withdrawal of such stop order or relief from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or a new registration statement and using its best efforts to have such amendment or new registration statement declared effective as soon as practicable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If, at any time on or after an Applicable Time but prior to the related Settlement Date or Time of Delivery, any event occurs as a result of which the Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, the Company will (i) notify promptly the relevant Manager(s) so that any use of the Disclosure Package may cease until it is amended or supplemented&#59; (ii) amend or supplement the Disclosure Package to correct such statement or omission&#59; and (iii) supply any amendment or supplement to the relevant Manager(s) in such quantities as the Manager(s) may reasonably request.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule 172 or any similar rule) to be delivered under the Act, if any event occurs as a result of which the Prospectus as then supplemented would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which they were made at such time not misleading, or if it shall be necessary to amend the Registration Statement, file a new registration statement or supplement the Prospectus to comply with the Act or the Exchange Act or the respective rules thereunder, including in connection with use or delivery of the Prospectus, the Company promptly will (i) notify the Managers of any such event, (ii) prepare and file with the Commission, subject to the first sentence of paragraph (a) of this Section&#160;4, an amendment or supplement or new registration statement which will correct such statement or omission or effect such compliance, (iii) use its best efforts to have any amendment to the Registration Statement or new registration statement declared effective as soon as practicable in order to avoid any disruption in use of the Prospectus and (iv) supply any supplemented Prospectus to the Managers in such quantities as the Managers may reasonably request.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;As soon as practicable, the Company will make generally available (which may be satisfied by filing on EDGAR) to its security holders and to the Managers an earnings statement or statements of the Company and its subsidiaries which will satisfy the provisions of Section&#160;11(a) of the Act and Rule 158.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Company will deliver to the Managers and counsel for the Managers, without charge, as such Managers or counsel for the Managers may reasonably request, signed copies of the Registration Statement as originally filed and of each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed to be incorporated by reference therein) and signed copies of all consents and certificates of experts. The Registration Statement and each amendment thereto furnished to the Managers will be identical to any electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. The Company will pay the expenses of printing or other production of all documents relating to the offering.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Company will deliver to the Managers and counsel for the Managers, without charge, for so long as delivery of a prospectus by the Managers or dealer may be required by the Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 or any similar rule), as many copies of the Prospectus and each Issuer Free Writing Prospectus and any supplement thereto as any Manager may reasonably request. The Prospectus and any Issuer Free Writing Prospectus and any amendments or supplements thereto furnished to the Managers will be identical to any electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. The Company will pay the expenses of printing or other production of all documents relating to the offering.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Company will arrange, if necessary, for the qualification of the Shares for sale under the laws of such jurisdictions as the Managers may reasonably designate and will maintain such qualifications in effect so long as required for the distribution of the Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Shares, in any jurisdiction where it is not now so subject or where it would be subject to taxation as a foreign business.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;The Company agrees that, unless it has or shall have obtained the prior written consent of the relevant Designated Manager, and each Manager agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, it has not made and will not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus&#8221; (as defined in Rule 405) required to be filed by the Company with the Commission or retained by the Company under Rule 433&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the prior written consent of the parties hereto shall be deemed to have been given in respect of the Free Writing Prospectuses included in Schedule I hereto. Any such free writing prospectus consented to by the Managers or the Company is hereinafter referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Permitted Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; The Company agrees that (i) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (ii) it has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Company will not (i) take, directly or indirectly, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares or (ii) sell, bid for, purchase or pay any person (other than as contemplated by this Agreement or any Terms Agreement) any compensation for soliciting purchases of the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;The Company will, prior to requesting the sale of any Shares hereunder and at any time during which it has requested the sale of any Shares hereunder or when delivery of a prospectus by the Managers may be required by the Act, advise the Managers promptly after it shall have received notice or obtain knowledge thereof, of any information or fact that would materially alter or affect any opinion, certificate, letter and other document provided to the Managers pursuant to Section&#160;6 herein.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Upon commencement of the offering of the Shares under this Agreement (if requested by the Managers) (and upon the recommencement of the offering of the Shares under this Agreement following the termination of a suspension of sales hereunder), and each time that (i) the Registration Statement or the Prospectus shall be amended or supplemented (other than (A) an Interim Prospectus Supplement filed pursuant to Rule 424(b) pursuant to Section&#160;4(r) of this Agreement, (B) a prospectus supplement relating solely to the offering or resale of securities other than the Shares or (C) the filing with the Commission of any report under the Exchange Act except such reports referred to in Section&#160;4(k)(ii)), (ii) there is filed with the Commission any annual report on Form 10-K or quarterly report on Form 10-Q, or any other document that contains financial statements or financial information that is incorporated by reference into the Prospectus, or any amendment thereto, or (iii) the Shares are delivered to one or more Managers as principal at the Time of Delivery pursuant to a Terms Agreement (the date of such commencement (in the case that the above-mentioned request is made by a Manager),the date of each such recommencement and the date of each such event referred to in (i), (ii) and (iii) above, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall furnish or cause to be furnished to the Managers forthwith a certificate dated and delivered on such Representation Date, as the case may be, in a form satisfactory to the Managers to the effect that the statements contained in the certificate referred to in Section&#160;6(e) of this Agreement which were last furnished to the Managers are true and correct in all material respects at the time of such Representation Date, as though made at and as of such time (except that such statements shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented to such time) or, in lieu of such certificate, a certificate of the same tenor as the certificate referred to in said Section&#160;6(e), modified as necessary to relate to the Registration Statement, the Disclosure Package and the Prospectus as amended and supplemented to the time of delivery of such certificate.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;At each Representation Date, the Company shall furnish or cause to be furnished forthwith to the Managers and to counsel to the Managers a written opinion of Wilson Sonsini Goodrich &#38; Rosati, Professional Corporation, counsel to the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or other counsel reasonably satisfactory to the Managers, dated and delivered on such Representation Date, in form and substance satisfactory to the Managers, of the same tenor as the opinion referred to in Section&#160;6(b) of this Agreement, but modified as necessary to relate to the Registration Statement, the Disclosure Package and the Prospectus as amended and supplemented to the time of delivery of such opinion.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;At each Representation Date, the Company shall furnish or cause to be furnished to the Managers and to counsel to the Managers a written opinion of Wilson Sonsini Goodrich &#38; Rosati, Professional Corporation, intellectual property counsel for the Company &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or other intellectual property counsel reasonably satisfactory to the Managers, dated and delivered on such Representation Date, in form and substance satisfactory to the Managers, of the same tenor as the opinion referred to in Section 6(c) of this Agreement, but modified as necessary to relate to the Registration Statement, the Disclosure Package and the Prospectus as amended and supplemented to the time of delivery of such opinion.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;At each Representation Date, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Davis Polk &#38; Wardwell LLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, counsel to the Managers, shall deliver a written opinion and disclosure letter, dated and delivered on such Representation Date, in form and substance satisfactory to the Managers, of the same tenor as the opinions and disclosure letter referred to in Section&#160;6(d) of this Agreement but modified as necessary to relate to the Registration Statement, the Disclosure Package and the Prospectus as amended and supplemented to the time of delivery of such opinion.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;At each Representation Date, the Company shall cause Ernst &#38; Young LLP (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or other independent accountants satisfactory to the Managers forthwith, to furnish the Managers a letter, dated and delivered on such Representation Date, in form and substance reasonably satisfactory to the Managers of the same tenor as the letter referred to in Section&#160;6(f) of this Agreement but modified to relate to the Registration Statement, the Disclosure Package and the Prospectus, as amended and supplemented to the date of such letter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;At each Representation Date, and at such other times as may be reasonably requested by a Manager, the Company will conduct a due diligence session, in form and substance reasonably satisfactory to the Managers, which shall include representatives of the management of the Company and the independent accountants of the Company. The Company shall cooperate timely with any reasonable due diligence request from or review conducted by the Managers or its agents from time to time in connection with the transactions contemplated by this Agreement, including, without limitation, providing information and available documents and access to appropriate officers and agents of the Company during regular business hours and at the Company&#8217;s principal offices, and timely furnishing or causing to be furnished such certificates, letters and opinions from the Company, and their officers and agents, as the Managers may reasonably request.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;Nothing in this Agreement shall restrict a Manager from trading, and the Company acknowledges that each Manager may trade in the Common Stock for such Manager&#8217;s own account and for the account of its clients before, at the same time as, or after sales of the Shares occur pursuant to this Agreement or pursuant to a Terms Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;The Company will either (i) disclose in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as applicable, with regard to the relevant quarter, the number of the Shares sold by or through the Managers pursuant to this Agreement, the Net Proceeds to the Company and the compensation paid by the Company with respect to such sales of the Shares pursuant to this Agreement, or (ii) on or prior to the earlier of (A) the date on which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Company shall file a Quarterly Report on Form 10-Q or an Annual Report on Form 10-K in respect of any fiscal quarter in which sales of Shares were made by a Manager pursuant to this Agreement and (B) the date on which the Company shall be obligated to file such document referred to in clause (A) in respect of such quarter (each such date, and any date on which an amendment to any such document is filed, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Filing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company will file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b), which prospectus supplement will set forth, with regard to such quarter, the number of the Shares sold by or through a Manager pursuant to this Agreement, the Net Proceeds to the Company and the compensation paid by the Company with respect to such sales of the Shares pursuant to this Agreement and deliver such number of copies of each such prospectus supplement to the NASDAQ as are required by such exchange.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;If, to the knowledge of the Company, the conditions set forth in Section&#160;6(a) or 6(g) shall not be true and correct on the applicable Settlement Date or Time of Delivery, the Company will offer to any person who has agreed to purchase Shares from the Company as the result of an offer to purchase solicited by a Designated Manager the right to refuse to purchase and pay for such Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;Each acceptance by the Company of an offer to purchase the Shares hereunder, and each execution and delivery by the Company of a Terms Agreement, shall be deemed to be an affirmation to the Designated Manager, or the Manager(s) party to a Terms Agreement, as the case may be, that the representations and warranties of the Company  contained in or made pursuant to this Agreement are true and correct as of the date of such acceptance or of such Terms Agreement as though made at and as of such date, and an undertaking that such representations and warranties will be true and correct as of the Settlement Date for the Shares relating to such acceptance or as of the Time of Delivery relating to such sale, as the case may be, as though made at and as of such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;The Company will use its commercially reasonable efforts to cause the Shares to be listed for trading on NASDAQ and to maintain such listing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule 172 or any similar rule) to be delivered under the Act, the Company shall file, on a timely basis, with the Commission and the NASDAQ all reports and documents required to be filed under the Exchange Act and the regulations thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;The Company shall cooperate with the Managers and use its reasonable efforts to permit the Shares to be eligible for clearance and settlement through the facilities of DTC.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;The Company will apply the Net Proceeds from the sale of the Shares in the manner set forth in the Disclosure Package and the Prospectus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations under this Agreement, whether or not the transactions contemplated hereby are consummated, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs), (ii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares, (iii) all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors to the Company, and the reasonable fees and expenses of the Managers&#8217; counsel (which shall be one outside counsel for all Managers unless otherwise agreed by the Company), (iv) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), each Issuer Free Writing Prospectus and the Prospectus, and all amendments and supplements thereto, and this Agreement, (v) all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Managers in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws, and, if requested by the Managers, preparing a &#8220;Blue Sky Survey&#8221; or memorandum, and any supplements thereto, advising the Managers of such qualifications, registrations and exemptions, (vi) the filing fees incident to the review and approval by FINRA of the terms of the sale of the Shares, (vii) the fees and expenses associated with listing of the Shares on the NASDAQ, (viii) all fees and expenses of the registrar and transfer agent of the Common Stock, (ix) all fees and expenses (including reasonable fees and expenses of counsel) of the Company in connection with approval of the Shares by DTC for &#8220;book-entry&#8221; transfer, (x) all other fees, costs and expenses referred to in Item 14 of Part II of the Registration Statement and (xi) all other fees, costs and expenses incurred in connection with the performance of its obligations hereunder for which provision is not otherwise made in this Section 5&#59; provided, however, that the amount payable by the Company pursuant to subsection (iii) with respect to the reasonable fees and expenses of the Managers&#8217; counsel shall not exceed (A) $100,000 arising out of executing this Agreement and the filing of the Prospectus Supplement and (B) in an amount not to exceed $12,500 per each quarter thereafter (solely for any quarter that includes a Representation Date). Except as provided in this Section&#160;5 and in Section&#160;7 hereof, the Managers shall pay their own expenses.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions to the Obligations of the Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The obligations of the Managers under this Agreement and any Terms Agreement shall be subject to (i) the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, each Representation Date, and as of each Applicable Time, Settlement Date and Time of Delivery, (ii) to the performance by the Company of its obligations hereunder and (iii) the following additional conditions&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Prospectus, and any supplement thereto, required by Rule 424 to be filed with the Commission have been filed in the manner and within the time period required by Rule 424(b) with respect to any sale of Shares&#59; each Interim Prospectus Supplement shall have been filed in the manner required by Rule 424(b) within the time period required by Section&#160;4(r) of this Agreement&#59; any material required to be filed by the Company pursuant to Rule 433(d) under the Act, shall have been filed with the Commission within the applicable time periods </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prescribed for such filings by Rule 433&#59; and no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use shall have been issued and no proceedings for that purpose or pursuant to Section&#160;8A of the Act shall have been instituted or threatened.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company shall have requested and caused Company Counsel to furnish to the Managers, on every date specified in Section&#160;4(l) of this Agreement, its written opinion and 10b-5 statement, in form and substance satisfactory to the Managers.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Company shall have requested and caused Intellectual Property Counsel to furnish to the Managers, on each date specified in Section 4(m) of this Agreement, its written opinion addressed to the Managers, in form and substance satisfactory to the Managers.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Managers shall have received from Davis Polk &#38; Wardwell LLP, counsel for the Managers, on every date specified in Section&#160;4(n) of this Agreement, such opinion or opinions and disclosure letter or letters, dated as of such date and addressed to the Managers, with respect to the issuance and sale of the Shares, the Registration Statement, the Disclosure Package, the Prospectus (together with any supplement thereto) and other related matters as the Managers may reasonably require, and the Company shall have furnished to such counsel such documents as they reasonably request for the purpose of enabling them to pass upon such matters.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Company shall have furnished or caused to be furnished to the Managers, on every date specified in Section&#160;4(k) of this Agreement, a certificate of the Company, signed by the chief executive officer or the President of the Company and chief financial or chief accounting officer of the Company, , dated as of such date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the Disclosure Package and the Prospectus and any supplements or amendments thereto and this Agreement and that&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Company has received no stop order suspending the effectiveness of the Registration Statement, and no proceedings for such purpose or pursuant to Section&#160;8A of the Act have been instituted or, to the Company&#8217;s knowledge, threatened by the Commission&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;since the date of the most recent financial statements included in the Prospectus and the Disclosure Package, there has been no event or condition of a type described in Section 2(k) hereof (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), except as set forth in or contemplated in the Disclosure Package and the Prospectus&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the representations, warranties and covenants set forth in Section&#160;2 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the Company and its subsidiaries have complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Company shall have requested and caused the Accountants to have furnished to the Managers, on every date specified in Section&#160;4(o) hereof and to the extent requested by the Managers in connection with any offering of the Shares, letters (which may refer to letters previously delivered to the Managers), dated as of such date, in form and substance satisfactory to the Managers, which letters shall cover, without limitation, the various financial statements and disclosures contained in the Registration Statement, the Disclosure Package and the Prospectus and other matters ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to underwriters in connection with registered public offerings as contemplated in the Statement on Auditing Standards No. 72, as well as confirming that they have performed a review of any unaudited interim financial information of the Company included in the Registration Statement, the Disclosure Package and the Prospectus in accordance with Statement on Auditing Standards No. 100.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">References to the Prospectus in this paragraph (e) include any supplement thereto at the date of the letter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Since the respective dates as of which information is disclosed in the Registration Statement, the Disclosure Package and the Prospectus, except as otherwise stated therein, there shall not have been (i) any change or decrease specified in the letter or letters referred to in paragraph (e) of this Section&#160;6 or (ii) Material Adverse Change, except as set forth in or contemplated in the Disclosure Package (exclusive of any amendment or supplement thereto) the effect of which, in any case referred to in clause (i) or (ii) above, is, in the sole judgment of the Managers, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Shares as contemplated by the Registration Statement (exclusive of any amendment thereof), the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;FINRA shall not have raised any objection with respect to the fairness and reasonableness of the terms and arrangements under this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Shares shall have been listed and admitted and authorized for trading on the NASDAQ, and satisfactory evidence of such actions shall have been provided to the Managers.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Prior to each Settlement Date and Time of Delivery, as applicable, the Company shall have furnished to the Designated Manager such further information, certificates and documents as the Designated Manager may reasonably request.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any of the conditions specified in this Section&#160;6 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Managers and counsel for the Managers, this Agreement and all obligations of the applicable Manager hereunder may be canceled at, or at any time prior to, any Settlement Date or Time of Delivery, as applicable, by such Manager with respect to itself only. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed in writing. Following any such cancellation by a Manager, this Agreement shall remain in effect as to the other Manager that has not exercised its right to cancel this Agreement pursuant to this Section&#160;6 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and any obligations and rights of the Managers under this Agreement shall be satisfied by or afforded to only such other Manager.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The documents required to be delivered by this Section&#160;6 shall be delivered at the office of Davis Polk &#38; Wardwell LLP, counsel for the Managers, at 1600 El Camino Real, Menlo Park, CA 94025, on each such date as provided in this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification and Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company agrees to indemnify and hold harmless each Manager, its affiliates, as such term is defined in Rule 501(b) under the Act (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the directors, officers, employees and agents of each Manager, any broker-dealer affiliate of a Manager through which Shares are sold, and each person who controls a Manager within the meaning of either the Act or the Exchange Act and against any loss, claim, damage, liability or expense, as incurred, to which they or any of them may become subject under the Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company or otherwise permitted by paragraph (d) below), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based (i) upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto) or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; or (ii) upon any untrue statement or alleged untrue statement of a material fact contained in any Issuer Free Writing Prospectus or any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Act, the Base Prospectus, the Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto) or the omission or alleged omission therefrom of a material fact, in each case, necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading&#59; or (iii) in whole or in part upon any inaccuracy in the representations and warranties of the Company contained herein&#59; or (iv) in whole or in part upon any failure of the Company to perform its obligations hereunder or under law&#59; and agrees to reimburse each such indemnified party, for any and all expenses (including the reasonable fees and disbursements of counsel chosen by the indemnified party) as such expenses are reasonably incurred by them in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by any Manager expressly for use in the Registration Statement (or any amendment thereto), any Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto). This indemnity agreement will be in addition to any liabilities that the Company may otherwise have.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Manager agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Act or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Manager or otherwise permitted by paragraph (d) below), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based (i) upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto) or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; or (ii) upon any untrue statement or alleged untrue statement of a material fact contained in any Issuer Free Writing Prospectus or any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Act, the Base Prospectus, the Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto) or the omission or alleged omission therefrom of a material fact, in each case, necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Base Prospectus, any Issuer Free Writing Prospectus, any Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto), in reliance upon and in conformity with written information furnished to the Company by any Manager expressly for use therein&#59; and to reimburse the Company, or any such director, officer or controlling person for any legal and other expense reasonably incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section&#160;7(b) shall be in addition to any liabilities that each Manager may otherwise have.  The Company acknowledges that with respect to each Manager the name of such Manager constitutes the only information furnished in writing by or on behalf of the several Managers for inclusion in the Registration Statement, the Base Prospectus, any Issuer Free Writing Prospectus, any Prospectus Supplement or any Interim Prospectus Supplement (or any amendment or supplement thereto).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Promptly after receipt by an indemnified party under this Section&#160;7 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section&#160;7, notify the indemnifying party in writing of the commencement thereof&#59; but the omission to so notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in paragraph (a) or (b) above or to the extent it is not prejudiced (through the forfeiture of substantive rights or defenses) as a proximate result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if the defendants in any such action include both the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and&#47;or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section&#160;7 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the next preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel (together with local counsel), approved by the indemnifying party (the Managers in the case of Section&#160;7(b) and Section&#160;7(e)), representing the indemnified parties who are parties to such action), (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party or (iii) the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The indemnifying party under this Section&#160;7 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section&#160;7(c) hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 60 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent (i) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If the indemnification provided for in this Section&#160;7 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and each Manager, on the other hand, from the offering of the Shares pursuant to this Agreement, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and each Manager, on the other hand, in connection with the statements or omissions or inaccuracies in the representations and warranties herein which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by them, and benefits received by each Manager shall be deemed to be equal to the total compensation received by such Manager under Section 3(c) of this Agreement, in each case as determined by this Agreement or any applicable Terms Agreement. The relative fault of the Company, on the one hand, and each Manager, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact or any such inaccurate or alleged inaccurate representation or warranty relates to information supplied by the Company, on the one hand, or such Manager, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&#160;7(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in Section&#160;7(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&#160;7(e)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no additional notice shall be required with respect to any action for which notice has been given under Section&#160;7(c) for purposes of indemnification.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company and the Managers agree that it would not be just and equitable if contribution pursuant to this Section&#160;7(e) were determined by pro rata allocation (even if the Managers were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&#160;7(e).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the provisions of this Section&#160;7(e), no Manager shall be required to contribute any amount in excess of the discounts and commissions received by such Manager in connection with the Shares sold by it pursuant to this Agreement and any applicable Terms Agreement in the specific transaction or transactions giving rise to the contribution obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Managers&#8217; obligations to contribute pursuant to this Section&#160;7(e) are several, and not joint. For purposes of this Section&#160;7(e), each Affiliate, director, officer, employee and agent of a Manager, each person, if any, who controls a Manager within the meaning of the Act and the Exchange Act and any broker-dealer affiliate of a Manager through </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which Shares are sold shall have the same rights to contribution as such Manager, and each director of the Company or each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Act and the Exchange Act shall have the same rights to contribution as the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any other party except that (i) if Shares have been sold through a Manager for the Company, then Section&#160;4(t) shall remain in full force and effect with respect to such Manager and the Company, (ii) with respect to any pending sale, through the Designated Manager for the Company, the obligations of the Company, including in respect of compensation of the Designated Manager, shall remain in full force and effect notwithstanding the termination and (iii) the provisions of Sections 2, 5, 7, 9, 10, 12 and 14 of this Agreement shall remain in full force and effect notwithstanding such termination.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Manager shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time, with respect to such Manager only. Any such termination shall be without liability of any party to any other party except that the provisions of Sections 2, 5, 7, 9, 10, 12 and 14 of this Agreement shall remain in full force and effect with respect to such Manager notwithstanding such termination. Following any such termination by a Manager, this Agreement shall remain in effect as to each other Manager that has not exercised its right to terminate the provisions of this Agreement pursuant to this Section&#160;8(b) and any obligations and rights of the Managers under this Agreement shall be satisfied by or afforded to, as applicable, only such other Managers.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;This Agreement shall remain in full force and effect unless terminated pursuant to Sections 8(a) or (b) above or otherwise by mutual agreement of the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any such termination by mutual agreement shall in all cases be deemed to provide that Sections 2, 5, 7 and 9 shall remain in full force and effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any termination of this Agreement shall be effective on the date specified in such notice of termination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such termination shall not be effective until the close of business on the date of receipt of such notice by a Manager or the Company, as the case may be. If such termination shall occur prior to the Settlement Date or Time of Delivery for any sale of the Shares, such sale shall, subject to Section 6 hereof, settle in accordance with the provisions of Section&#160;3(e) of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;In the case of any purchase of Shares by a Manager pursuant to a Terms Agreement, the obligations of such Manager pursuant to such Terms Agreement shall be subject to termination, in the absolute discretion of such Manager, by notice given to the Company prior to the Time of Delivery relating to such Shares, if at any time prior to such delivery and payment (i) trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited by the Commission or by NASDAQ, or trading in securities generally on either the NASDAQ or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or FINRA&#59; (ii) a general banking moratorium shall have been declared by any of federal or New York authorities&#59; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity involving the United States, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment of such Manager is material and adverse and makes it impracticable or inadvisable to proceed with the offering or delivery of the Shares in the manner and on the terms described in the Disclosure Package and the Prospectus or to enforce contracts for the sale of securities&#59; (iv) in the judgment of such Manager there shall have occurred any Material Adverse Change or (v) there shall have occurred a material disruption in commercial banking or securities settlement or clearance services in the United States.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Indemnities to Survive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The respective agreements, representations, warranties, indemnities and other statements of the Company, the officers of the Company and of each Manager set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by a Manager or the Company or any of the officers, directors, employees, agents or controlling persons referred to in Section&#160;7 hereof, and will survive delivery of and payment for the Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All communications hereunder will be in writing and effective only on receipt, and&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If sent to Goldman, will be mailed, delivered or telefaxed to&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Goldman, Sachs &#38; Co. LLC</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">200 West Street</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10282</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (212) 902-9316</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Registration Department</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If sent to SVB Securities LLC, will be mailed, delivered or telefaxed to</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SVB Securities LLC </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1301 6th Avenue, 12th Floor </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10019</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  Peter M. Fry</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If sent to Cantor Fitzgerald &#38; Co., will be mailed, delivered or telefaxed to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cantor Fitzgerald &#38; Co.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">499 Park Avenue</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10022</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Capital Markets</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (212) 307-3730</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cantor Fitzgerald &#38; Co.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">499 Park Avenue</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10022</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; General Counsel</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (212) 829-4708</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Davis Polk &#38; Wardwell LLP </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1600 El Camino Real </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Menlo Park, CA 94025 </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Alan Denenberg</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (650) 752-2111</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If sent to the Company, will be mailed, delivered or telefaxed to&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Denali Therapeutics Inc.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">161 Oyster Point Blvd.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">South San Francisco, CA 94080</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Steve Krognes</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; krognes&#64;denali.com </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wilson Sonsini Goodrich &#38; Rosati, Professional Corporation</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">650 Page Mill Rd</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Palo Alto, CA 94304</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Tony Jeffries</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">email&#58; tjeffries&#64;wsgr.com </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any party hereto may change the address for receipt of communications by giving written notice to the others.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons referred to in Section&#160;7 hereof, and no other person will have any right or obligation hereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Fiduciary Duty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby acknowledges that (a) the purchase and sale of the Shares pursuant to this Agreement is an arm&#8217;s-length commercial transaction between the Company, on the one hand, and the Manager and any affiliate through which it may be acting, on the other, (b) the Manager is acting solely as sales agent and&#47;or principal in connection with the purchase and sale of the Company&#8217;s securities and not as a fiduciary of the Company and (c) the Company&#8217;s engagement of each Manager in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity. Furthermore, the Company agrees that it is solely responsible for making its own judgments in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">connection with the offering (irrespective of whether a Manager has advised or is currently advising it on related or other matters). The Company agrees that it will not claim that a Manager has rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in connection with the transactions contemplated by this Agreement or the process leading thereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any Terms Agreement supersede all prior agreements and understandings (whether written or oral) between the Company and the Managers with respect to the subject matter hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any Terms Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed within the State of New York.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement, any Terms Agreement or the transactions contemplated hereby or thereby.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any Terms Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The section headings used in this Agreement and any Terms Agreement are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Recognition of the U.S. Special Resolution Regimes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the event that any Manager that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Manager of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event that any Manager that is a Covered Entity or a BHC Act Affiliate of such Manager becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Manager are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As used in this Section 18&#58; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BHC Act Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covered Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any of the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b)&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b)&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Default Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. Special Resolution Regime</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The terms that follow, when used in this Agreement and any Terms Agreement, shall have the meanings indicated.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Shares, the time of sale of such Shares pursuant to this Agreement or any relevant Terms Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the base prospectus referred to in Section&#160;2(a) above contained in the Registration Statement at the Execution Time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated by law to close in New York City.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities and Exchange Commission.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Designated Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any given time, a Manager that the Company has designated as sales agent to sell Shares pursuant to the terms of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) the Base Prospectus, (ii) the Prospectus Supplement, (iii) the most recently filed Interim Prospectus Supplement, if any, (iv) the Issuer Free Writing Prospectuses, if any, identified in Schedule I hereto, (v) the public offering price of Shares sold at the relevant Applicable Time as specified in a Terms Agreement and (vi) any other Free Writing Prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of the Disclosure Package. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean each date and time that the Registration Statement and any post-effective amendment or amendments thereto became or becomes effective. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Execution Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the date and time that this Agreement is executed and delivered by the parties hereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a free writing prospectus, as defined in Rule 405.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interim Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the prospectus supplement relating to the Shares prepared and filed pursuant to Rule 424(b) from time to time as provided by Section&#160;4(r) of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an issuer free writing prospectus, as defined in Rule 433.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Base Prospectus, as supplemented by the Prospectus Supplement and the most recently filed Interim Prospectus Supplement (if any).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the most recent prospectus supplement relating to the Shares that was first filed pursuant to Rule 424(b) at or prior to the Execution Time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the registration statement referred to in Section&#160;2(a) above, including exhibits and financial statements and any prospectus supplement relating to the Shares that is filed with the Commission pursuant to Rule 424(b) and deemed part of such registration statement pursuant to Rule 430B, as amended on each Effective Date and, in the event any post-effective amendment thereto becomes effective, shall also mean such registration statement as so amended.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 405</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 415</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 424</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 430B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 433</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; refer to such rules under the Act.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#91;Signature Page Follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">#95429626v9</font></div></div></div><div id="ia20891ed49c841ec8918b3ac741a3b94_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the foregoing is in accordance with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall represent a binding agreement among the Company and the Managers.</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Steve Krognes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IGNATURE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AGE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">QUITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ISTRIBUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">                                                                                                                                                                                                                     </font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONFIRMED AND ACCEPTED,</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">as of the date first written above&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Goldman, Sachs &#38; Co. LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SVB Securities LLC </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cantor Fitzgerald &#38; Co.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IGNATURE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AGE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">QUITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ISTRIBUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">                                                                                                                                                                                                                     </font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ia20891ed49c841ec8918b3ac741a3b94_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">SCHEDULE I</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule of Free Writing Prospectuses included in the Disclosure Package</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">None</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule I</font></div><div><font><br></font></div></div></div><div id="ia20891ed49c841ec8918b3ac741a3b94_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Form of Terms Agreement&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ANNEX&#160;I</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DENALI THERAPEUTICS INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock ($.01 par value) </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">TERMS AGREEMENT</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________, 20___</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">name&#47;address of designated manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Sirs&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Denali Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) proposes, subject to the terms and conditions stated herein and in the Equity Distribution Agreement, dated February &#91;24&#93;, 2022(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), among the Company, Goldman, Sachs &#38; Co. LLC, SVB Securities LLC and Cantor Fitzgerald &#38; Co., to issue and sell to &#91;Goldman, Sachs &#38; Co. LLC&#93; &#91;SVB Securities LLC&#93; &#91;Cantor Fitzgerald &#38; Co.&#93;.the securities specified in the Schedule I hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchased Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#91;, and solely for the purpose of covering over-allotments, to grant to &#91;Goldman, Sachs &#38; Co. LLC&#93; &#91;SVB Securities LLC&#93; &#91;Cantor Fitzgerald &#38; Co.&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Designated Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) the option to purchase the additional securities specified in the Schedule I hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#93;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;Include only if the Designated Manager has an over-allotment option&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;The Designated Manager shall have the right to purchase from the Company all or a portion of the Additional Shares as may be necessary to cover over-allotments made in connection with the offering of the Purchased Shares, at the same purchase price per share to be paid by the Designated Manager to the Company for the Purchased Shares. This option may be exercised by the Designated Manager at any time (but not more than once) on or before the thirtieth day following the date hereof, by written notice to the Company. Such notice shall set forth the aggregate number of shares of Additional Shares as to which the option is being exercised, and the date and time when the Additional Shares are to be delivered (such date and time being herein referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Option Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Option Closing Date shall not be earlier than the Time of Delivery (as set forth in the Schedule I hereto) nor earlier than the second business day after the date on which the option shall have been exercised nor later than the fifth business day after the date on which the option shall have been exercised. Payment of the purchase price for the Additional Shares shall be made at the Option Closing Date in the same manner and at the same office as the payment for the Purchased Shares.&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;Include only if the Designated Manager has an over-allotment option&#93;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each of the provisions of the Equity Distribution Agreement not specifically related to the solicitation by the Designated Manager, as agent of the Company, of offers to purchase securities is incorporated herein by reference in its entirety, and shall be deemed to be part of this Terms Agreement to the same extent as if such provisions had been set forth in full herein. Each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Terms Agreement &#91;and&#93; &#91;,&#93; the Time of Delivery &#91;and any Option Closing Date&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;Include only if the Designated Manager has an over-allotment option&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, except that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annex I-1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">each representation and warranty in Section&#160;2 of the Equity Distribution Agreement which makes reference to the Prospectus (as therein defined) shall be deemed to be a representation and warranty as of the date of the Equity Distribution Agreement in relation to the Prospectus, and also a representation and warranty as of the date of this Terms Agreement &#91;and&#93; &#91;,&#93; the Time of Delivery &#91;and any Option Closing Date&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;Include only if the Designated Manager has an over-allotment option&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in relation to the Prospectus as amended and supplemented to relate to the Purchased Shares.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An amendment to the Registration Statement (as defined in the Equity Distribution Agreement), or a supplement to the Prospectus, as the case may be, relating to the Purchased Shares &#91;and the Additional Shares&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;Include only if the Designated Manager has an over-allotment option&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the form heretofore delivered to the Manager is now proposed to be filed with the Securities and Exchange Commission.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the terms and conditions set forth herein and in the Equity Distribution Agreement which are incorporated herein by reference, the Company agrees to issue and sell to the Designated Manager and the latter agrees to purchase from the Company the number of shares of the Purchased Shares at the time and place and at the purchase price set forth in the Schedule I hereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the foregoing is in accordance with your understanding, please sign and return to us a counterpart hereof, whereupon this Terms Agreement, including those provisions of the Equity Distribution Agreement incorporated herein by reference, shall constitute a binding agreement between the Managers and the Company.</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ACCEPTED as of the date first written above.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Designated Manager&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annex I-2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Form of Terms Agreement&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule I to the Terms Agreement</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title of Purchased Shares &#91;and Additional Shares&#93;&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of Shares of Purchased Shares&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Number of Shares of Additional Shares&#58;&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Price to Public&#58;&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Purchase Price by &#91;Goldman, Sachs &#38; Co. LLC&#93; &#91;SVB Securities LLC&#93; &#91;Cantor Fitzgerald &#38; Co.&#93;&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Method of and Specified Funds for Payment of Purchase Price&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By wire transfer to a bank account specified by the Company in same day funds.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Method of Delivery&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Free delivery of the Shares to the Manager&#8217;s account at The Depository Trust Company in return for payment of the purchase price.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Time of Delivery&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Closing Location&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Documents to be Delivered&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following documents referred to in the Equity Distribution Agreement shall be delivered as a condition to the closing at the Time of Delivery &#91;and on any Option Closing Date&#93;&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The opinion referred to in Section&#160;4(l).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The opinion referred to in Section 4(m).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The opinion referred to in Section&#160;4(n).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The accountants&#8217; letter referred to in Section&#160;4(o).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The officers&#8217; certificate referred to in Section&#160;4(k).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Such other documents as the Manager shall reasonably request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annex I-3</font></div><div><font><br></font></div></div></div><div id="ia20891ed49c841ec8918b3ac741a3b94_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit B-1</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20220228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:aec18fb2-6110-4082-a409-d742dcaf2e3d,g:0ce9a24c-0bad-4576-a9f4-8c303ed05681-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20220228" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20220228">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20220228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20220228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>dnli-20220228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:aec18fb2-6110-4082-a409-d742dcaf2e3d,g:0ce9a24c-0bad-4576-a9f4-8c303ed05681-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_3c977a4e-a862-46ba-ad99-f8d9e9d2a8e1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_29d3756d-eb7f-4968-ba20-8de01ed931ca_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_30188531-77ad-4919-a320-4b75d905aca5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_349ae6ff-d682-4346-b042-d601ba41ce7f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_56bde710-db33-4bbb-8653-451f10c359cf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0cc91606-4d27-4625-84e4-fc59e1c8bac3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_197c22be-1e97-45fc-b9a3-812b58d66272_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0a3d836e-f9cc-4fb8-a321-834418526191_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_23e62366-4db1-46da-a999-a51265c267e5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d102b417-d15e-47f4-9be4-7dbe44c030b0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_69e8284f-8495-45c7-8e31-fa760f354fb4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_c63ac7bd-ab1b-406d-8937-04c7e83116c9_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3a58023f-5390-4931-8e82-a16e7838d2d2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_87d80148-4c4c-4be9-92a2-e28071f6c6cd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0d22d9c2-2500-4794-8525-8d48cb47f032_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_45e5c491-10f4-4cff-8ddb-8144d1c4efa3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c18fb706-5238-4d6a-a2c3-50a2de78027f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f387e829-a626-40a9-b7ac-fc586b6bca02_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cec3494b-1f6d-4f84-81d0-e622449ea4a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0b79cd0a-33ba-4d5f-9fa6-94b3e23673bb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5fed8b61-5a59-4ace-bf3e-83dc665454fc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6ed8b893-83a3-4db0-95f5-94718a26909c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>dnli-20220228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:aec18fb2-6110-4082-a409-d742dcaf2e3d,g:0ce9a24c-0bad-4576-a9f4-8c303ed05681-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20220228.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b510de95-ba35-4a85-b79a-983c46d9caa8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_DocumentType_b510de95-ba35-4a85-b79a-983c46d9caa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f5550047-5edd-4a38-a76a-c4d95712e7aa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_DocumentPeriodEndDate_f5550047-5edd-4a38-a76a-c4d95712e7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_13352917-77a5-4e31-a7f4-8050a21262d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityRegistrantName_13352917-77a5-4e31-a7f4-8050a21262d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8c688d58-0e62-49fb-a13c-20fc8a269bca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8c688d58-0e62-49fb-a13c-20fc8a269bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e193ab1f-7171-422e-acf2-b408a42a7ed6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityFileNumber_e193ab1f-7171-422e-acf2-b408a42a7ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c80d2948-ccaa-4db0-a8a2-41128fb55559" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityTaxIdentificationNumber_c80d2948-ccaa-4db0-a8a2-41128fb55559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f9be952a-826d-4706-8fe1-ca8214b57ff8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityAddressAddressLine1_f9be952a-826d-4706-8fe1-ca8214b57ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d8472d7a-e0cf-40ba-a2b2-1458acdc8023" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityAddressCityOrTown_d8472d7a-e0cf-40ba-a2b2-1458acdc8023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a38549b9-86bd-4849-bf72-d82264d4aefb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityAddressStateOrProvince_a38549b9-86bd-4849-bf72-d82264d4aefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fba26292-85fa-4d91-80d6-6380f24a663b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityAddressPostalZipCode_fba26292-85fa-4d91-80d6-6380f24a663b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_34ca817b-c5b6-4b45-a4fe-4d39a1447462" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_CityAreaCode_34ca817b-c5b6-4b45-a4fe-4d39a1447462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_52a0e15f-921a-4a60-8acd-ef7fd81f7f21" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_LocalPhoneNumber_52a0e15f-921a-4a60-8acd-ef7fd81f7f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5990bff2-b105-4add-8e03-0b651130c3f5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_WrittenCommunications_5990bff2-b105-4add-8e03-0b651130c3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7ffd0a28-7c8c-4e86-a614-6347fa418066" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_SolicitingMaterial_7ffd0a28-7c8c-4e86-a614-6347fa418066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c78aacf4-0b54-4e2e-9f61-08473581e178" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_PreCommencementTenderOffer_c78aacf4-0b54-4e2e-9f61-08473581e178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_eae9b914-47a4-4d95-a2d1-7d4fd5832eb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_eae9b914-47a4-4d95-a2d1-7d4fd5832eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_454bb0f6-90dc-4df7-b851-cae09600ee76" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityEmergingGrowthCompany_454bb0f6-90dc-4df7-b851-cae09600ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d9b8e761-07a7-44a0-9616-8a1e91869f82" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_Security12bTitle_d9b8e761-07a7-44a0-9616-8a1e91869f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0b38fbce-18b9-4a8d-84fe-d8ee44131fb6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_TradingSymbol_0b38fbce-18b9-4a8d-84fe-d8ee44131fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f9d557db-53a8-4f03-ad4d-995f86b054a0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_SecurityExchangeName_f9d557db-53a8-4f03-ad4d-995f86b054a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f093e80d-78ca-4194-9c98-f29b1866d51a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_EntityCentralIndexKey_f093e80d-78ca-4194-9c98-f29b1866d51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3a498eae-7b26-4552-8a4a-f85b77c2f773" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1a45350-5ae6-44df-a794-68cca5f444c3" xlink:to="loc_dei_AmendmentFlag_3a498eae-7b26-4552-8a4a-f85b77c2f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140085624285704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>dnli-20220228_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20220228.xsd" xlink:type="simple"/>
    <context id="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml80L2ZyYWc6YTg2M2I4YWY2NGQ2NGE5Yjg0ZmQ5ZWU5NDU3ZmE5Y2MvdGFibGU6NGRiM2I3MTAxMmJjNDY1M2E4YTYzNTA0OGI0MWM2NWUvdGFibGVyYW5nZTo0ZGIzYjcxMDEyYmM0NjUzYThhNjM1MDQ4YjQxYzY1ZV8yLTEtMS0xLTc0MTc1_ec676274-a915-414e-bb59-8da274b73e92">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml80L2ZyYWc6YTg2M2I4YWY2NGQ2NGE5Yjg0ZmQ5ZWU5NDU3ZmE5Y2MvdGFibGU6NGRiM2I3MTAxMmJjNDY1M2E4YTYzNTA0OGI0MWM2NWUvdGFibGVyYW5nZTo0ZGIzYjcxMDEyYmM0NjUzYThhNjM1MDQ4YjQxYzY1ZV8zLTEtMS0xLTc0MTc1_0f6544d7-45f9-4210-bebe-eed828ed2930">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDEz_9ed5222b-1660-4e02-9727-4b5c5171b831">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8yMjg_9aa5eb52-0022-4e14-bbad-e7560ae5b3cd">2022-02-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDEx_06da7f57-45e7-42e7-99e8-1ee90c0a330f">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MWE0NzRlZGM4Zjg5NDc3ZWJlYjA5NGZlMDQ2OTU1NDcvdGFibGVyYW5nZToxYTQ3NGVkYzhmODk0NzdlYmViMDk0ZmUwNDY5NTU0N18wLTAtMS0xLTc0MTc1_dabcf8d6-2e7c-4935-a402-0aa5c2126e98">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MWE0NzRlZGM4Zjg5NDc3ZWJlYjA5NGZlMDQ2OTU1NDcvdGFibGVyYW5nZToxYTQ3NGVkYzhmODk0NzdlYmViMDk0ZmUwNDY5NTU0N18wLTItMS0xLTc0MTc1_8041de92-c194-48dd-acef-1a4aab848a90">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MWE0NzRlZGM4Zjg5NDc3ZWJlYjA5NGZlMDQ2OTU1NDcvdGFibGVyYW5nZToxYTQ3NGVkYzhmODk0NzdlYmViMDk0ZmUwNDY5NTU0N18wLTQtMS0xLTc0MTc1_fba7ba96-0693-4bf6-8f89-40a195a818b9">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA5_437a1b8d-e3b1-4803-87fe-4ef2ab7c40c4">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA2_8e2c5afc-8352-416b-a627-6d9025ceb12d">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA3_e89b9a5c-c8b1-4959-a19f-13bfe8a5e955">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8zNzA_2ca46a74-2203-4af1-a94d-9d634010fe7c">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDA4_dd15390d-18b3-4da5-9ef4-7595762f05bb">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGV4dHJlZ2lvbjo1ZDY5OTM3ZGFiMDY0NWQ2OWI3YzI0ZDc5ZjI2YTFjNF8xMDEy_0a7469e2-6fe0-49e9-a9b8-35ce9d456f05">866-8548</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8wLTAtMS0xLTc0MTc1_b0d740e4-b95c-470b-9fac-ec1511f147c0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8xLTAtMS0xLTc0MTc1_13dcb63a-9602-48fb-8857-def4cd98fb91">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8yLTAtMS0xLTc0MTc1_e53bb13f-9004-4291-8e89-8266066e078f">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6MGZjZmRhOGNkNmJkNDdkZWEwMjU5ZTM1YTVlMTVhNzgvdGFibGVyYW5nZTowZmNmZGE4Y2Q2YmQ0N2RlYTAyNTllMzVhNWUxNWE3OF8zLTAtMS0xLTc0MTc1_760b8d7d-0e80-4575-9c41-3c7b3aa00049">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6NThiMmJlMWRhOTJmNDI1Mjg3NGQyNGI2MzAxNTg4YWYvdGFibGVyYW5nZTo1OGIyYmUxZGE5MmY0MjUyODc0ZDI0YjYzMDE1ODhhZl8wLTEtMS0xLTc0MTc1_9e047859-0b08-4595-9f99-a2044e79d742">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6YzBkOTliMTM1MWZmNDU1NTlhOTE4M2I5NmM5NzAyNDYvdGFibGVyYW5nZTpjMGQ5OWIxMzUxZmY0NTU1OWE5MTgzYjk2Yzk3MDI0Nl8xLTAtMS0xLTc0MTc1_d3219a19-0a24-47b3-95ff-cb07a5a697ef">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6YzBkOTliMTM1MWZmNDU1NTlhOTE4M2I5NmM5NzAyNDYvdGFibGVyYW5nZTpjMGQ5OWIxMzUxZmY0NTU1OWE5MTgzYjk2Yzk3MDI0Nl8xLTEtMS0xLTc0MTc1_1dc7e17e-1767-42c5-b649-fc49c1237c6a">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8503fc7cf6c340548aedd783fe567836_D20220228-20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmZkYTBhN2Y0ZTRmYTRjMmM4MzNlOWFiMTBiOTVhYjUyL3NlYzpmZGEwYTdmNGU0ZmE0YzJjODMzZTlhYjEwYjk1YWI1Ml8xL2ZyYWc6NWQ2OTkzN2RhYjA2NDVkNjliN2MyNGQ3OWYyNmExYzQvdGFibGU6YzBkOTliMTM1MWZmNDU1NTlhOTE4M2I5NmM5NzAyNDYvdGFibGVyYW5nZTpjMGQ5OWIxMzUxZmY0NTU1OWE5MTgzYjk2Yzk3MDI0Nl8xLTItMS0xLTc0MTc1_b0e0f7ee-9a8f-4296-8134-ca4972832cf0">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)4IB%M(B$O;[E^%U+\2(ZH6!XH[^30MKN83$9%DA]P9B&JEPH15+#<>0ZH6
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 6(M<5*K$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !8BUQ499!YDAD!  #/ P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C
M3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=
M(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B
M63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.Q
MD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[
MV?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D
M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( %B+
M7%0'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ 6(M<5"^5N7KN    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 6(M<5)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !8BUQ47SNCI#@$  !!$   &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 6(M<5)^@&_"Q @
MX@P   T              ( !>PP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !8BUQ4EXJ[',     3 @  "P              @ %7#P  7W)E;',O+G)E
M;'-02P$"% ,4    " !8BUQ4JL0B%C,!   B @  #P              @ %
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 6(M<5"0>FZ*M    ^ $
M !H              ( !H!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 6(M<5&60>9(9 0  SP,  !,              ( !A1(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  SQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20220228.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dnli-20220228.htm">dnli-20220228.htm</File>
    <File>dnli-20220228.xsd</File>
    <File>dnli-20220228_lab.xml</File>
    <File>dnli-20220228_pre.xml</File>
    <File>exhibit11-8xk.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dnli-20220228.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "dnli-20220228.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20220228_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20220228_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dnli-20220228.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20220228",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20220228.htm",
      "contextRef": "i8503fc7cf6c340548aedd783fe567836_D20220228-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20220228.htm",
      "contextRef": "i8503fc7cf6c340548aedd783fe567836_D20220228-20220228",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001628280-22-004300-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-004300-xbrl.zip
M4$L#!!0    ( %B+7%2:+GW? QH   ZH   1    9&YL:2TR,#(R,#(R."YH
M=&WM/?M7VSK2O^]?H2]WO[OT'!S\C.W0LH<F@4TO<5H(Y2:_],BVG!C\R-H.
M>?SU.Y+MO(% "9"6GGN!Q-9H-)JG9B1]_/?(]] MB6(W##X5A")?0/\^^OA_
M'/?WY_,S5 VM@4^"!%4B@A-BHZ&;]-"53>(;Y$2ACZ["Z,:]Q1S'VE3"_CAR
MN[T$B;PH+CV,RIA8@N:8(E<2!)Z3>4WDL,SKG*W*HFUA1R22O=\M\Q;1L2A;
M'&]BFY,5M<1AW9$YS9)XB=B\4M*$?;OLV)C'JB,3V<&R)5J:)$$[4^!-7<&F
M(M)N>PF,#D88Q.61YP8WGPJ]).F7#PZ&PV%Q*!7#J'L@Z+I^P)X6\E=C=]V+
M(L\+!W\WSBZL'O$QYP9Q@@.+Y*U6X(_,R,L;2@?TL8GC_/6[,:$XYS#=4;(>
MI!L /$+GZ"")<! [8>3C!.80.A-YCA<Y09P#PL7$6@ $GXO=\/9>.(+"\1HG
M"3D<F\S(PA#)@< #VNWT1?K0O8<4RY1S1W>]+$AS&++7RQX.NI\*). N+PHP
MP03;1Q]]DF!$(7#DOP/W]E.A$@8)L"W7&O>A%RO]]*F0D%%RP.A[</2/?_SC
M8^(F'CFRH0>.,BS\IWT\2+_\>)""-D-[?/31=F]1G(P]\JE@NW'?P^-R$ 8$
M$'!'9?HBB=(_7=LF ?L3GAL@.Y%KI?V/DG/B?"JXFL)+CJ5:3LF29%Z1-4QL
M6]4DAR@E^%7Z4<U1F>)40 'V:=?$+=<"P&]<@>%$V*L'-AG]1<8%Y-H VI:^
MC\UJ>'LFGM^VI<; OJ[==D[UZZ;?N6FW/O<,L<UW6N=^NW5^W? ;<F-B>,VK
M$[?1^NPV6]][[>O+\9ED>.U)W^^<UH;MENT;IY=\QZ_Q[<F7ZV:U,>FT/'@/
MGEW?".VKNM#P-/Y,[(S;5U:IW>J*#;$NMZ_:HG'Z#?ZO*>WK+K3_IG2N+A6C
M>BD!+*4M-F[MTQ/7/+TL&:?G+K21&JWC4</_<FU4VT)#K,GM5GMBM([YYFF=
M;UPU1./J,FOS'?I2@DXKY#NG]4G[VAHUJK5QVV_PQO7EI-WJ]8SKAM"H?I/;
MU]]&[4E;Z'S7QF>M6M*XX$=G+8MOM"SA![%*:DE49= MP.BR(!/.-!6=TVP,
MWYHJ*!.Q<,2#S*N"K.GZQX.%2=WF'!^#RK6IVCWQ<+> 4ID$L*.D[+@C8G,.
M]J@B>9_T^R=]LC+IO%-29-E6P:HX.B>+8(9,8A*.$%L3-6*+NL07CDZ.SRYJ
M*_-]L"C?$7%(1$"+Q6O4$E7VY9C9"> (Q*Q+.0%E]*D0NW[?HZJ/?=>+*,,L
M:*#B*+8!Q,$BC+3_6:<9#G$XB-@GIG/+&1>FG/$4+LP!$:9F\D^N33\[+HD0
M0XBLM265^E^+ K/<^"C_:A%Z'^@;VODG, U14@5GXXAB1"T95<K+SZ9HVG>\
MFC_)/^>='"P0*J?JE(P'<_K\ +1^JOH9.1_R-WX(A?DVF;GPW8#K$>H3E:52
M/SD<NG;2*PL\__\%]M[1Q[B/@:/,Z !:IW^G0*:@CCXFV/1(#M$,(T"/LT+/
MP_V8E/,_#G/+E%I,CC4Z]''4!13,,$E"OZP !N#L):Z%/0Y[;C<H4S)DCV?(
M%?D4P03(D-AYS]GC(GMTD-BKSW2MJ/-W/^:+PO39 8,=Y2_D-.HG!=8.1D6)
M\:D@%98&G@U%["<H#CW71G_P[-]A]CP)^V5AY6$?V[8;@'.)!-;%#(<#1JAU
M4Y>2CL+3@&Z,4"G-+&!@$A72N<M?!XS#J)SWYP"#@9[V76]<_M=QY&+O7_LQ
M.%C@B46NDSZ.W0DIBSS 9A^'*0E4:,TF,".)(%*"7AKU5JV*+EK'K=K%(J/,
MH?RZ.%[4*I?G]5:]=H&.C2JJ_5WYSS&8 U1I-AKUBXMZT[@3\44VA;D]G*.^
MN#WJ"\)&([O"<0^X)PF#?50M5HH0WRBRGH]F9\13T(JJ*FPDGH\"RQ=%57MV
ML))25)7G!PO8ZH+^_& I;>4MJ;ZUVNNG7UU4J(LZ<[W"W YV&ZOAT@:*P,36
M33<*!X'-93K!8?\.MZO[3IKG#;3%F"!?B4DCVM?T_$>YYV]<?1.;K9N)(9[#
M.\>B4?U^8UQ[KB$VQA )2,VK]MCP:^"-?P,O_KML_^>+UQ&]6_,Z%#K5MM)L
M-:0.>/>-:IMGL*[J4GM2YSM52^E<U\5VZ^3:.-&HIS_YH1-;$471Y(12B>=D
M LZ>KHK@R)N*I8#':6H2^%\:]]>JW_ZNI-^5],XKZ56O]NUHZ+M4\KJH9OO.
MJB!NI+#!53VO&2UT7OO:/&\]Y)AN:GVVB_/7010/<)"@)$07Q*+KM'_^(93X
M0T%"880$9<_^\$;)'3HHZ1&*]2!R$Y?$J#:R>CCH$G1L)0@>"[HD[\8TT(4%
MBO$YZ8=1@O;RSP1''HPL0>26YDPB]IC8'\KH:7&/_.HC?0&'YBM;F*FERS6+
MBYTV?,/YT&>/-N-L/.;&0&..!+^7!S1N7'=_Z!@KA*:U>+K6)1-!YDR:'R.J
M4N(Q44S)LL$-)68TP-$8B=H^2\*]NT/O[M OZ [M3LRZ126^86BZ]6SD.>FZ
M,4T?)P8\^;UT,XU.1S_XDHU51Z%Y)0(_1/BAZT3C!$)TWN*Q)/$.^ TD "9
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M D^>RRJPP;<$2P\) -;P(TIX+:NFR>V1NLBJ#-/%::)@/H0\4CZ>07YS3([
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M*$%OI.9?&!.7ZBAVVRX:N#\"?C$S5&,HYK)(_>P+/9E*>Q44=2+Z!>%C1K.
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MPX$8ZU?XW=H85K/4!FV]B8DX:VOJ'4ML3YS[HUH5)IF/,+FD,F\6Z]'42%
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MG]\G9\_?"WKIU)(6[H8OV<)1^ZN]7D:G^1(FM!G\;L^=[4J\<R6T?;.!:)R
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MZZS=0).R@C.;DE)(5."V/./"/MV8$S2OD=(6ATHO>!C'7IQ3D?*UUX8B*&#
M/TCCW4P"?686(\ F2GLWTH *O(W#(-UY+8M1::#@&4]LZZO5NBK<?&X.HG1.
M[<O@V=B=<2DVDGFP&DWW*0*3(OCZT*+N]RF"XZW?&"NDF2ENDY9[!#\(_>?E
M=".^1#KV!;H&3=-N*0%3K=R4I']6N7 _4TWL'#G)5^.>>T=RVE_L@XT4'B(.
M1EM\$YT&9(AU#B3-QN0)N&&C).@<M</"8-'HE_Q#%\DHAJ2IFG&J=/=S8ETO
M)P[*'%L-F!I!'%PA5!4:*S*8%8$ZLC\S9T,W5;;626M];O+:;(_@BZ;6^,V'
MUF%6*IL\RCAKPCPP@259UF*;4R<8+DD"5XN:NG9JL.>&I-*'U/$+@-%\4<Y+
MJ3]7F)ZRTOOO;>HN>=,)2Z:%ZE-[-=.2EA Y\EZ]*6XGDQL91:Q'@0#'"TN8
M-8J=T(W\1:)@(2&'\!=(CXBC%J.-*+(:G7CK<:X'6( %M;2LD6*Q8 [0(FOQ
M)QTRAQ#FS$&\,S%6Y[,8</R8,&T'$#=^*<,'.X_?ZK9;1!KN PLU="@Z[8HJ
M7]WCI\E%,Z#BH$R7_[WGGY9$LW 0T7IQ3O">!S'76?*/(6MA_D"\P>5J6@J(
M_8 5%:>/'OR# 98H(J K(Q?\MZP&4P,P\AA42IY-\AFPF^%2LE$<4#9YTRJ7
M!>DD.H(S(NG;$"D0]8CF0""=*%$A3DUCL9&.-"CM*4VI7+L+U=+6$\3G4_,L
M;-2E7<@,4P1R K"B<'DBCN2(+[=%H[RH=]E=%'0TBZ;5HWF_K-UOJ-PR2O40
M=O>;*CL</9JZ7=S1<W6F$D7<\A=HBXF& 0!<PZ+! /-.%&YW01#N328 (%8>
MF 3'T&NZ3Y*88^:A8_-B@:]&P?@FK)4H.68/JH8)S5KRVF?$#S]ZI 8X^&'F
MV:&IY\,EX*:#Q*JG7CG$T?!<D^L- XSA68((IJT7BLSU>_.EM6.IVBV\IZ%.
MQ7AM6;LAU[ F/?820\V9AQJ#KGU9Q8OD8K^DR!@%Q$S#9KHV'" O \E&94B]
M_?<>X7Y>\0N@7<5LY!2E!N6*K]E?%47MWV6BF;GY?C1MZ>Y1\,P*T?J1*/)?
M)A7YR\R5/^M\4" RP@"U8_J99LIA.8BL@/#SE4Y.PMH$HT0[-0;1A34.AU28
MP&[V-^K#Y&RTGJA6LJIKQ$%GBACJAZE]13L.I)*YV4A$T07/N\-Q*X9XNU)2
MP-#,9VZ$U!UO[!S<AX9"@]'$,47+TNRN!-\O!&JCUK3C)P*O>Q6%/TQ(DN(O
MHQ-/(+!A-;<D/&:-"8 GLQ649=D)T^0R'UM20*'(O>V LE2JEJ,K+@W,M$3%
MYCY3EX/8V"$^P9ZG**7PR!<?%^1A5!2Z+/0PRE?8+*K_Q;S@1"_<3%+D&M3H
M#L/T>2\,QLJ6< @6$&-#4:=Y0 ;Q/Q3Q$PC(L=1M?9A4]?^D*&?=)(NR70PK
M[,RY,$ E9VMRD:[PHVY)L6Z#*5,!TEBW85EFD3,W^H7#PGJ?1[%YE&>'EIJX
MSZ,<;QY%=K?G:WC9\E,M'?:.[D["]):WD#+.S>*#TU)A2?UCI [4<CY:^#PC
M(Q'L.)&YUGC.-;63*46-U7P*J:5%CTX#3\15G#=9F]-)8IL^^>;4H8#5O\>1
M'L()S!7:23Y@]-RN!EO*?6'L=\V#V)I;+^[CU-H>!1?6TSO&A66VPBU37[UW
M8Q-,'T*F-[,M!,%"C$S_(;B<7HQR@%2<13D\U^9%K\=RVOI^KFC,TN'R< "F
MZ")ZMB*W4A HD^D JJE53I67 0O?VP'.@M.O'RMI \$*LY:H<&<C_CZ?&WA7
M_W4G[^@Z6:/H',;)J-4#21 &!EW0__3I@QS) D_[;:W@W=D,,%CO[+UE9EZA
MV5FNXA<9^.7W&$\(VC#$&(TEI.)>J?P@ON6NU, 7 :NPVU\GU8"AFNYN Y'E
MT-88?1TK<(S?K3<FA.+,O#>W;J<I#05EETW)<2<\>9MAWF/"=4WH,I-O=:FY
M69*XU4@0Y+5"Y;V@GY>',33M&K4@WX"<;@*!453W6@"[&1L_A(V[+$$39"Y(
M3I->2[9(3/):^IB<<)<CFP6#"Y^ST22IN,[DXIX]^.^4UH!XRTHB 5JMBE::
M%$X@\QI=,ER>LNA&ZQ8,:98:+*PRZRRIR=B6Y0A8Q*^Q+KOVKY]+F)(IA]C"
M>3&GV4=#0:Z'XW8XRO ?[AZ'=&Z-@23[/DXVQ,31:+@<W7?NX0(O>WES#*+C
MC#$BUFB6YP[6.-BO3ED!,NN=M]F:SD%2M4\?/SV9SRQ1B$V3^X]*3I  4KI7
M<<0=GZT]N4J;G;6]:GKF+)T):QC&R:FY.2^+._>!LI,XG4SM_G-)S[!3Z3SC
MIN9IXITQFNJ_M!W/.*]FDPEXCVHC^\83KM2/JY9="$O.>%J#3Q>S5#,2EA&>
M8XQ^"VY^J2>/OG^8W%L&>UL&=IM@?[G"7]23LYF=.6\;2WS+E7D-3COE812R
M9\V'Q4@ZD;.=PNL(*/C?W_,HTF2,^MJ]KH84;'VQZ83\S.'U"IN[;U^3,L+Y
M]DGKX=MCVX]9&5$-QVGK7F&;QTS(<'Q%L/0-O)Y5X<0A3CPV/F<6G84V#\$T
M-&,6_#==NJQFS@WMB'!1G\]LZF91E&O3?9D!;[U/FF JJ$Y>S/1"11W:0U5%
M26P/F)CETN30]S1[R777WVS5Z<YU#B#6MP$JQ2]N7]=P?YV\-+-C(DB1UQ3V
MM;Y9&];+3GO&4QY9%]8EY9X>A=Q/2S=)68LTX73>QZA-C/J;0PO[WL>HCS=&
M/3# F*N<'84@VY5W_IK N+T>-;X>&#IS\/CZ*]"+;?1 %_U4"I>)4I==P-KT
M12TJ7[++F-X2I(\BV=A=,?T+VND6!<_.G%X]%/S^871(C L:5&51SQMS^ 8<
M:"[M&M_PUP'6UOS&#UHH\89Z![_ :=;EY<*^^V^8#G<>?*^+##$M)IOCD>8X
MJ[*PT:5GG\"J?QD:\7^PZ^Y=Z%'/B7JWQ+Z.D$S[^2G7"]#]=#2I]\#6*?TW
MSZ#:E&9.J!/Q^XJLK4I\5P26ENBBK!J5.UI"J=HWO#K>:V*/B&+I%*SZ0W >
M[(16P 0UU8-$+2$!!S1VKF&#;;/ "$]&)>:QM203;!P)VG(_A .2,VYM-"P7
M;)J:$8?$87S##:P.DW#\U=*G#F<I9N<>H=I^92TU=_"J(M06"RIN\28AAB-U
M0@(D5UQ;HVV_X4H;68D$'CFB)MCPA.,\?3L$71XSBZ'&ZBJ26FE%T)DVZ?XE
M7NDK$3"3:K,@\U[ ,>+/5SBSNJ=]=U78P?0UW.I;42+^]?T%]W[$Y"9*-P:D
MP RMBHRWULBOQ#BIQ F,BRG+ #>!*1 G\Z2;83R.6<[KC:N%(E.+[O2":E<8
MM"G\\1)1\LXO;6K)]35XQ?A\BSV"6IJUF.A4O>-:R&)ZVU[#G)^EVVZV'Z?-
MY/N7HE!_Q5-1R:!=3QPOPE=WHG?B_!S)MI\F6S[^4(YV)MU3X?A5[+0O7:&_
MZ]I'>7))QX=:!OUZ:BQ@H)K>H'B7;W/M.8:^[< =ZP@_BAM&(9T.GF'RB+>[
MH>GEUI>]0U?BRV 0/1*K/R3+"A-?AE!2E6RH?<,HK3$'2=P$W2*!Z40[V\<"
M=$'\%E,:;8?0&1 [,35MD!F#N0J0]@.ZJ6]N^?.]W1AR@-.[533QMC"1,EUD
M WW*]#]E<3/UQ?4"<S=APJ$4L(&+LHSI/R%CZ-IAK723<5>.3Z)+[R#RM((O
MQ)Y,[#Q]NN,^>Z:Y=<^BRQ0Q=D@;.HVO#03,IQ6R1X?U/>#V+U_\_>SM3*-L
M$CO=)-+UVRW+=TIP3!ENH+N<%L=[- 1W=A0/3LC,+$P<:](]/-RIV=JV]RZ?
M?E\^NV<,-R'"QX\.+>IV'R+\(S&&3Q/,CB)/AO1OI&2V]P/EICU@\[1(T:>-
MOZVMT4[WAHX?**DVK!94QHYH%#ZBA!4AG<LY+1PR_(JY!^WI+3U%'*._^$@L
M#IW\CJX@FX<H :> ,+W#J)$W8- 6TJK>7D\FFRV=WGTS3GJ/7ESIH[EX'%?"
M]O6F"Y#B$ P6CB1N >9,S,4T9DG;BI4HPY@PU4(M\%P7?=O4DD0EMDGIZ:0P
M&JE*XTG=E>2E<\^TJNJ]SNQ>NRBOG_O[2.P4>1CYQTS[2+8H^(T:#I?R][91
M,G"98+N&H<NHV<PCL7&F:14_DS:@@'>35 V71D^ZZO/00<'MDU52##TOK,<N
M5Z+)\;LZ[RESYU!BVM5*@?5-V^P5HNK;Y =D.?Z7-"0(KHNC)LC=MPS^4P8W
M27[DAGL^UVB!SG>[NGNM\(?4"M-\E:.YI$I:W-A^#D45P5[)-!OUJK(KBQAS
MDVL[74]#BFS1:-@"@A)+ZL7:D9!SJT$ JXV,3M'AYWAXEO-A//K[+E\3Y.#"
M?X/EE!RWM&64*C@AA1<OS4:H+0Q_52S'REJ<H_L8!*R;*UQ 65PVLW!/HM]-
MFDTRF1;0K+$JB6D6[:7D)"DKVTG8 RS U(<H(8EOP!+MHYOB.*YKO(2.K&GM
M%98<S0FQ91^%);5CK"C,?VVF[4A4T#2)GJN"G):Y!HB//7VSSO*64=2.4\R"
M7>;TGT/WW#G@+Y.'B?98UP/==DNP13>NB.\_HCBOT\YA&NRLW)PBXA0G=\"X
M'']B.,226-BB^0]G=SB-:4#J=Y@/I"2S,2.Y>Q.M_J,&#]J+R=IYVCX[X"5F
MF.>C+V=[H>5CE@-! 63-H^!Z004_N5?DVQ3Y3CGTVQMLY^C@IA!^:R2\QX1\
M%9UFJY@X= 'F)R[:*WD8,S(SD69<NG2PA=OPWG4I7+$HE;N#H0,NM<2A<$J\
M,6;NQ)3=:C6B[N4)!4VY)]%6/6&B<JNLZ(.X*B1]N_/-V5':Q^&AO):,@W,_
M[D XC1<?R=8*@RXY_>HIW0>4BEM@(>[0SC<(TG[N'G%+)^(9N*HX%U@?=RA'
M;J+D0U&LMSHE?[S@^^FAQ;/O@^]_I.#[-&_DR+%&\XUJ2L&$2YWF\QB&UK]2
MU\>13DIT8*EEMB*HA>,FSSGJL9 CD8O4&N7G)=^GS^:@:/YMVDO"6Y=K#:@8
M:L32P9!J8C)(+&+8B)O;9]+GD!TD>MJX()@Y+69"Z#POR0M//2KE=;91P ^R
M'GI%*738]P5H;]L9R2.MD!A>P+PST](2VVR'0Y2@OL6<,#T[O?$>B9\U38 7
M2F1J89,2=E04>83AVB>/=^&94JIEVAE=2-P%[B?NV=;;L7-<[Q\XG@X7I]'2
MMJ \U&"*R(PU#7$4RMPJ>/D#./'@FIP[#![R"F[=3],R9,IQFQ1+A4^L>GY#
MZ?--CAN<X'3".VD>/.[[7N:6]X"&)I4X<!RGG037?R5F[Y$(]!::+P2H"VNZ
MP;OY,1Q/(46I;[1<D<4U$+89]TXA)#S;B9_Z.+^5E-L5GN3>KU[@9@%FK\R<
M>(4E E>>@GUKSJQ+-X&F]=0P%H:B&;Z-L$&<^(FRSFE!Q?Y$8W)-+@/]S36)
M[F&TJSJ1CJCG,\&X31GCM@J1R,$G*!8DC:'-CPABYKJ<L79.>#S.+.T41@B[
M+<D3!O<047D;(2J'E_G54)V/+_A'JB=FH&%(BH0@LXMSFJ.:,Y][5!1"5;\'
MI83K&(T*DGJG!,D283E-T[SFB=A1$@V9IG73EBYGMD0Z0KS_]F[<S&ZE72$4
M2VBW^XE+56&B*=F\N2P>X 4P(45NBE7+CN-W+L/G+'6?8*DP [VB-!OC"SD"
M'\@5: #374)QZC2J R$-CW0Z.PSJ+M>X%2X+80M!2 N9TA*EG,R6$I<<;=;,
M/=&3W(1#K.1J.55D/N+Q"<L=87KS-.UF- 9-G;*18033V;]!T[;"&^HV+?75
M21%1T8HF1(U588O7+;PX< F!TAE5P%A>?"_*YPGJ7$(CG6[;7K;MCMFBLG[%
MDDOO&Y>=(CG1W/)%%@*(NUAD\R::S!&AN'.8]HT=$/.WP]M793%8'>,:@KX4
MB4%!#23ZHD:UV>U:OPXI@D>+^(FM]2:YEZX_&^X"NT9_.!='8KY6.UM%1@7\
M-Z@FJXIBB!ZJ:&!0SYB[2G,!XIS@<ORKK- E?]> -5J7R=^;)F]QT__EST^>
M?0<S@QHIQ65?<J\0V,;/Q01@]\9_F"&0/(#S2,9RJ\F8VWQ_6 Q:F\,XA!O;
M()DEQHEN;3OVTNN?L64M3$RDEN:,)-OQD$D5K'ME^_$YCWHX6+-Z)_2QO.1]
MQL%F'!X?6A#_/N/P1\HXK'XW>^(0K(@2=GJ%N%,,>B 3(MB'FQ$Z65_L &R+
M5^Z W\B _["6QF$:&MN%ZBC,C^2KD\616QYW2FO7OTUKQS;.'.;[O 5AS1_(
M\)?T?]_];AVILTN0J3=-]4'4^+^R-K_"'H@__OCF-K?ZR.FTVXB//*UX&1]5
MM(NM3',Z[D"V>!<?W0['(X_%[>YW_ZWL_N:F;#8VU%ZV==?+WOM?D/ASW'@'
MTYKC;(&[$ 3_=GLI1,_]O$"R/(KBVE%N#ZZ;J!HQFZG1'%B^-ZPO]C1!IC7'
M7AIBN5-#W+Q22/?1"EX&CE_E2!3!^K<I H'<L&;D1#8-*W/0,&$)8>'W%HQP
M66"/PP%1*4D^8&44S!AE;*7Y\R<*IW:_E+;TPE+D-F^\M BL%?W(Q52X9!;X
M]]3>]2_W:P-%9S;<H+Y0V"UGZVJO9X _ YK")=)!0A10:P.9L#%,1&F(X0]+
M9^RV8IK@C*82RDSJX;:CW3QZ0ZW!K<I5V8NGS#@AQAK;_#Q)CB$IL?6.]/F"
MRJ,P$X[,].NVY'VW+!?J[LL+!6LBB*^6RC);6]\ES>IKP_@O/T!5?/KU=VY^
MGI^B72(%#LVZ55 <>-1)98L7E0C31)V"I_C)QF9R.:6YL$9$J6QC[YCNJD<\
M+BJ<7R<5T>NFOQ#$>G T\':"[=NW):D-K9GBJ6Z%NBML&@UG@4+II&[ *[C"
M:<;?%IJ:]GJL&3I5N=R(4G-5JQY@+BL)!>EGS9)[A%0E2?"\P+*Z5 633TSJ
M/RIH%,(&,MXJ0+$B2]NV#I !S^T(57(D$M/NCW0N2CJC$)@F7DNA#<W/&+X4
M-G<A_!(NXS\,@"ERR3_8>G!Z+@L!\#FVK0MI%P4+Q0=?M!<O]<.;>TT")A&6
MH3;&"U\7/9HV2/UK0!CAN>4!D:E[;ZS6S>$P9IA"1!"WC4:AUHQ(]=A0F7V7
M7AVQ?-:^JN6 OD_MF-3.DT/+EMRG=HZ7[#V2D6'.RE '>BJ0H9.^'O75J%]J
MAG=?@A*&BT4A4J])-LU5RXB&L=R<$UW)H]V/$:T[UBKCMPM) FRO(X-$#?S5
M147A#E1;_DLI_P.]CM-1/+?>$IJIWH!"ZF_#CFF>KMC; T%-_L" Y,-$2]IN
M55- [1B V4*G]^A7I0[DU.V1R5";^8XL 5="KF<!["/WAW7\N_$F_KU]5\MD
M9'=)?$+E!5Z?O7MQ]@^RLUJ_R(;QQP)Y/Q*CMMM*0B]38BN!0JH&7N&:.P)U
M6WI+?T54FFWRU<GY3-0AE@/.(]A8J31Q-LA>//:CS<D$$:+HI+[NZJ*A\BPJ
MXJ9]8HKQE,(G\)K5*[;\U%EM;VU^+=5U&G,:,VWP3:AXD8**2P$<F#O@%& U
MH''XCJHHKY^4LY=$VK= F'+0^\EV/8E,N*,8')II4QU4F/Z'CF[8Q&X>>JMI
M#!<])_*0;+DLG1:D%/.-4*KXC'%(:(^4$INH;SS%E2)N>NL%0SE<<T4$5;W#
MSZ:OXZ/<J= 53)EM>C.&3<_,?;TPM+-$W#^+/@T+2';"TET+A8_#/OO U6 :
MX-WQTDK/MF7@H<+0V(@(C$L:$WDW>Y]1]<SHEWA0Q==PKYF( /1WO/WO!-H?
MO:ATLSL2=33L'\M1ZO0]FNT*BLP*&FN.JJ1D! DAQPCQC%,[@S%E/K,;_N)X
MN/<N_] =+^)>;HHBD&G@?YYU91?O!ZS[5L6ETM+'+J#FC=)*391JZDU;PROI
M=FLX$K&[VFN/ARDRLP8>ZE.50'S?,U?G>..#2)Q3NR_<^HNJ #\/CQA2MO:$
M<B.OPBXA9_N+]\^/9"T^7H-^D[HZC-Q+8Y='>#8D;P+#K-$!=)V0O?/R]P!_
M&P5^>FB!U?LH\.\-\'_RU:TIBR\?3NF*VXL"\MSD2$)&Q^6W=%#B57_ZVYML
MH[B-ET*_?*ND=5&VNH:9ANBHZS#9O\2/R5U6RF@PF@:*/4]@->"4(UB%-$#"
MXU#"V60_Q,@^,(+)'<FY5^8.S =:(!@^:9EP<UAA?73NLLB-<1^49,7W<M^#
MF+O50#2=1+U(@'^".!9C1IWBA3J;)J@^;[-+_(NFSC -8 C+H$?Q(>BXX[LM
M/1X;,#Q7:V2XY8,J-K/>"&.4N\)H@+;C:-G\&("!!P@0./5P0^L!%FQ!X!+&
MCY"A2Y^YD"([>*(3:MHPNILZ%J0QB":'II:4C,U@E$]<?!0F1Y#48N@[6#VO
MP 6_-M:8$-!::E8)Y?F1'5JDRYD5^&N*.O4(,[@B%H94&%(P0%2NURH>,4+M
M"1_<D;(8R4AJ6G7 (X0:M$OW:HTQ2_=FY1_!$3$J@7:79<SWHP&&,E]7/>"J
MD6D6^AB4 D29]$U;%QNSYEO431B3"_JG1)9(V+4-VPU.-I/?G!CZ*NY\ JJE
M]\%0 7V[_KQ5"B)^&7'T,&X7H7CG:*39K-;)XGZ"+NE.F\PK;$CX84-,\#2%
MQ"P_R;B4BO21?&D:[GN\R3NXR;NAO2PVRDN*(;YB!6=2G0\KF_>+KQUN9:5=
M<@&T$2[YU)L573B=3%SSTN,,HM4-]:Y@!FE0"*^[!&&'=_WAU>NWIOEU3^%#
M@^*-:+Y+I<(92U#6=<VBI).#Q$*B)B%\J7;\9[[A+EVJ+\]K;'7ZN0_/-" M
M5#8?I^[I;/I=RE*4WBR,ZT:V@)E1_V5A?L%I)"$5R9DWS8<',.[6"(V^#XQ:
M!LVZGG=N1%L&2>E7H*Z2TZ?XY#>X/UZ]VJ'V*$?^L=SK69]HA%A6O673VO0I
M=WA3<GI[=JP,ZL[V;DR^9/YLI9U+DXOFJKCD+*HR'JT(8@<F%2UFH,'<T!&B
MAN6^?(C'.K9_RB%J<VD82<;@U]DL^0_P$5(P,T-Z?\F*D!(8)5"=_3SN^^)P
MG2GD@?H Z%20<=?H&/[C]''Z)3P>5HO/)84JD#9BJ.&)\)<M1=?:2ZC; J&E
ML;(@@@>?/<1P%H;-B?)*Z &#=627X4L:;IB-_#I11D-/&?)<2B\51,E>U68=
M;C 0<XN^U5=WS+=Z;G/+LE=^=G9[L#5NW^MJI@<7)T/4$SM,HQF;V&F2H32'
M&>)QL\7&GE;;<X1\_KFFC"HJFR[49F]FV"]-_A2G*=U5FF$!%D%S^G24B\/K
MQ]E[9@!L1CI^G+"=5OF6^XU4F>&9S'*6H:QRL J@Y)]]=QS!U6QK<'5DZT>[
M<J4>TD5!2%XN(9:=L)T0^!H_$LL4](BF9V,/5UWR/+&G(55,>#S2:,4N=-L4
ML;>SE9/3(;F='.&V8>P8]1Y$GCQ4K[WX/LT_QC2B3YY@-6N06(J_7VR5G+=Q
M6?SMBW7W&&@;_9X*-M]'OX\Y^GU+RAL/U$5;S@4?P*U?R COK$[2ECZH3VOP
M*?IF+=W3F2TY5[?>M%VG:K3M7IF8W4K[36:&I-7QB,6,9ZAA*,B9ZS#6G)JC
MH2Z5GA]TU[H1:OLIUN-GQOW'7/3H(=II*1=0*O95 1OE2#*A\VMDI86@70-%
M%/]#B$ENKGMNZ1Y,8?:(7:%&TMQ6X.!X4'+@=\S'7$4)4U :8FP1IX_F#[ZT
MX<O?0OUP)&NZN)$UC1(G[;W"F2+*8@N</#U9[;^V>0Y*J1OS7_V!5SC?NL)!
M ,'OJT"1YZV,,6DRW6QX_\U;1Q?8Y1(AW.9V1A6X0FJ)#95# %@D%V):0F+A
MK9WIK>E3:HI8(0WC4R=]<\Z91E/</G9R9DYFBT&3U*RB%_)TSUV/%#^7;3$N
M[G66W"..$_)T"=*Y93;ZK%AQM9$ <XZ"6XU7R F_XDPN'.[4D8'N*V]P)#NM
MN*XNM;.N/'[&N9HB\KO.MOH0W591DFJ3')6N1>+6+2[*PH1>+PV_@.U+472<
M-XD0/_!O;;(07Y$^DG0M!VOE?L$H)G:PJ>H8L:7CJ)V4D/N&--.+#,L6$/Y:
M?(2UU]ZC-\"3%,E;H7EJ,Y*]]@X?)2#EHZR_X8#.Z:-GA]A4RQ40[C-DVO?<
MC%^03IGW7#EU;?-^PK!/ T2!P2V86J/4L?V="(G$-,@A.I;5GE[NKL1S$U\]
M=Q3-JNEZ6GGJ/!/I5N(V&8WLM2UG:EN06-&"F7[7J'4T<,IX['ZS1LBSNJZ.
MI?D8-29G5Y*3@R@C_4EC;V<YJ'P0WN<$A#Z,DM+"Y+$\V"K/N$5&70?)>EQ;
M8[LJ#'(?J9OXX-(@$&"F.)LL37P<(0&+%D:9T"J1I\#-Q*25@]06_!0?<51=
MM>$$L[(0^>>P">D<RU)-EWF$5@UZG>@^EGF9M=1JF<P+[5S+%CRVT+T0>!=K
M-3_38TLU]%*G$+5ALA5*>K$Q*$DE:?9E?NO<L_>80\PZW0/#;6C\JT.+-M^'
MQO](S._+&XFSL65JT:Y]$W'??ZN[V!CC1PK[R/S^V#.YQP3D+PKPHFQWK*VB
MI7L3 "V'*J1 6K];(_RN&? 0\CK'N<^=3;J(OX7%EP>CS]>Z*@).Q>CZ\,>7
MH/YAC'$CUH]015IXW8SCR>$@#0.!^P1C:4%X>>Q2T&_%1?%78MC"H856A;ZV
MP=@UG*W%V.K$ BMLU4*P=;F[4>M?>6$G>5,G9T/.^%[XM,ZS-H=]UCQ,OGY,
MI<<46^3;8,VZ*;"FN!.)NST0,X5J"EO.4&=X;WHN)]CCK0]'*$7?Z?CTY2F9
MX:[-2?IHUO:9 M"#QX'6>JL]) WZR9\<,EHM>PQVJE.:T7@ 5-G_7&?RJ.AE
MSR=/B'?&DY;H-(;B<H+1L_:3]LV.?,/D*GO?S0FUZ_)9("JIO9R7J:S5$[?8
M3AM%H7(7Q&YQ-2\8JWFQP$!R<"[9I76"^B&4UY<==8."7LI*K3?A1]^ #XLD
M"-70<7 T\?NB>JUY;2#?"6#JVG&W2)P:G(P))JUR9MY'&H26G-<BOZZIBN27
M(3]W>7@="OW&XG@X#<+SD'5<P?\!:X23<K5NL;IIP>%:T)P(O&?$C8FJ65_2
M[=L[49P4;00_762R93)[MDUFUU'"UU^<(]$E%Y.ZA$L8@MW99F57<!Q;P!3V
MI/?28<NL;"D.BY-MH=]N:);+(DC&,)QQ+A91#$)Z)),]'>9Y;S=""!418@W>
MBRO,8LL? YB;+3Q^1+K1.Y4@-H@@%FV!.'(I+!!:&*&U"IX[U9'^2-;BE\FU
M>*/1$8(;[(?L#0AK]\F=DG(:,V@Q.&IH>VYE8 [JU*^*\VDQ)*\;N=UGI[>^
M1<OQU5(<R# P%M@(X],^9G,LAVI95H0N17H6"6:."B]\.M[2&X*'._"6R_8-
MIP,9?UI47<$\+5,<W,(=-\7$'W=?8^W<II$7,:0^UB^-(?X.IE9ERX85A5AF
M@2/ &<QX=H@.:B,87-E5*7VT%]E=L*F4G% ?'QX[90_ON 0%6&T>@HO$B#]-
M\]+(F 7&UAV<8[(PY'1$WE0I*L7"1A@^O-+Z0IK1P^03,4ZA3B>+AOSB8?*#
M!>0K\ZCW[+!90Y1Z'7F2\*Y.S)W'R&Z\)=O+>DID<6$4\C:1$8\4+LK!QP\/
M'S1B2POVQWTTV$2#OSZT .M]-/AX@=**$7'U+QG0>,V>U5:VJLKD?YCZ-D,N
M)S'H4$FZC6;DEL=A%Z Q/4D99N/$VGPE:AMX5TI B3%(=$;]5J0CW F>\BAY
M627/$5W4@(.;56GR4U%7#58:?TB3YV?)-T\?/?[20EX=8.(VB^0X5N_K.U:]
M^0K^N:HMVP+NU^=P/Z7+N-6"S>/PU;;7_HU9@$I9$D[$7R#[-_C6*^)4<;O2
M,#0<"6^KDGL,87@/-QO&)B@T6BPU&4-5*E\^.L7*.:](C:GIT:X]!"#0F;[-
M84!_*!!?(K*DX2:8W)(I33#0UVR4",!VH/+7!]=UWC8?BA9V7U85K5TMQFA9
M6YCY!3G K3'%EL*=N4.9[%!D8[BQ;:K.N8M30[@JLEJRDM+H1I>[F>":S,XS
M1/_1F*NF0^J'*BM7F'Y<$?(,ACU'XD,ZC:7DGD1.^2 (+V@:*VRT>HF/_95X
M68MF92NF(S2<WKA,4\1E 1=RL%;X6^!_!_(CJ^Q**&*$)I..J053?\B7-HCO
MTXXZ#(\2-T5BQW-MZRW>EW,5["GV:MSPL!9G" E0F'/SGL\TE!(A=D+[^0SF
M!ERO&0:ZNV:9M68S[[T8Q*RC\3"G%T6OV>XP1DT/)/X)K$%G^@F,"G1(=DH<
MK3/&L'/&D<!6G5><5E7%.5&8AM^A<)M /+K\^Z:&^27&$7%,*(CH-EHSZXS
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M2569JK-MUH@KJY%6&51=+(7 <TSI"JHS1^KDA:L)HJ#R?32;X R!PD>X7E$
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M,C(X+GAS9%!+ 0(4 Q0    ( %B+7%1\-6LW40H  !A=   5
M  "  = <  !D;FQI+3(P,C(P,C(X7VQA8BYX;6Q02P$"% ,4    " !8BUQ4
MMLU,%K(&  #P,   %0              @ %4)P  9&YL:2TR,#(R,#(R.%]P
M<F4N>&UL4$L! A0#%     @ 6(M<5#G29L"6EP  .EP$ !$
M ( !.2X  &5X:&EB:70Q,2TX>&LN:'1M4$L%!@     %  4 0P$  /[%
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
